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Abstract 
 
Pharmaceutical and metabolite residues have been reported in European 
aquatic matrices since the 1980s. Discharges from municipal sewage treatment 
facilities have been identified as the primary source of these residues in the 
environment. Reported removal rates from wastewater treatment plants are low 
and residues are found to be persistent in the environment. 
The extent of pharmaceutical pollution in Irish waters is currently 
unknown. Therefore, the aims of this work were to develop an LC-MS/MS 
method for the simultaneous detection and identification of twenty 
pharmaceutical compounds commonly used in Ireland and to establish their 
influent and effluent concentrations in three wastewater treatment plants 
(WWTP) in the greater Dublin region. Results of a twelve month sampling 
programme, from the three plants, were then used to determine any seasonal 
variability in the occurrence of pharmaceutical contamination. 
A combined SPE-LC-MS/MS method using Strata-X cartridges for 
sample preconcentration was developed to investigate the occurrence of the 
twenty pharmaceuticals in WWTP streams. Analytical separation was achieved 
using a reversed phase Sunfire column with gradient elution. Fourteen of the 
twenty analytes investigated were found in the wastewater treatment plants. 
Concentrations determined in the effluent streams were in the low µg/L range 
and consistent with those reported in previous studies. These concentrations 
are below known toxicity levels however the cumulative effect of discharged 
residues may impart a negative ecotoxicological effect. No correlation between 
flowrate, BOD, COD or suspended solids and WWTP effluent concentration 
was observed for the analytes. Seasonal variation of effluent concentration was 
investigated with respect to rainfall, temperature and sunlight hours. Again, no 
relationship was identified. Correlations were difficult to determine due to 
suppression of the analyte ions in influent samples and the potential for 
conjugated metabolites to deconjugated over the course of treatment. This work 
has established an inside into the level of pharmaceutical residues present in 
Irish wastewater treatment plant effluents and can be used as a baseline for 
future work in this area. 
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1.0 Introduction 
 
Pharmaceutical compounds are an indispensable element of both human 
and veterinary medicine. In recent years the presence and potential effects 
of such compounds in the environment have received increased attention. 
The first reported occurrence of pharmaceuticals in the environment was in 
1976 in the USA. Clofibric acid, a primary metabolite of lipid regulators, 
was identified in treated wastewater at concentrations ranging from 0.8-2.0 
µg/L (Garrison et al., 1976; Fent et al., 2006; Nikolaou et al., 2007). 
Following this, pharmaceutical contamination in rivers was reported in the 
UK (Richardson and Bowron, 1985) and municipal wastewater in Canada 
(Rodgers et al., 1986). However, pharmaceutical contamination in the 
environment was not researched in depth until the 1990s with the 
introduction and availability of methods capable of detecting trace 
contaminants in complex matrices. Since then numerous compounds have 
been identified in a variety of aquatic matrices including wastewater 
effluents (for example Ternes, 1998; Andreozzi et al., 2003; Bendez et al., 
2005), surface waters ( for example Thomas and Hilton, 2004; Zuccato et 
al., 2005; Kasprzyk-Hordern et al., 2008; Peng et al., 2008) and drinking 
water (for example Jones et al., 2005).  
Although the toxicity of pharmaceutical compounds to both aquatic and 
terrestrial organisms is relatively unknown, a number of reported 
investigations have shown that pharmaceutical compounds pose a real 
threat to the environment (Oaks et al., 2004; Fent et al., 2006). For 
example diclofenac, which is frequently detected in aquatic matrices, has 
been found to have adverse effects in both rainbow trout and vulture 
populations. Diclofenac accumulates, with a concentration factor of up to 
2732, in the liver of rainbow trout and causes histopathological alterations 
in both the kidneys and gills (Schwaiger et al., 2004). In vulture 
populations this drug has been shown to cause renal failure and has 
resulted in a population decline in Pakistan (Oaks et al., 2004). These 
studies highlight the potential danger to both terrestrial and aquatic life. 
Moreover, they underline the latent risk to humans. 
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Wastewater treatment plants (WWTPs) have been identified as the main 
point source of pharmaceuticals and personal care products in the 
environment. These facilities receive a continuous input of compounds, 
either in the parent form or as an array of metabolites, as a result of usage. 
Reported removal efficiencies in WWTPs have often been low - for 
example a WWTP in Germany had a removal rate of 7% for 
carbamazepine while the average removal rate for the fourteen 
investigated compounds was 65% (Ternes, 1998). Compounds not 
removed were released to receiving water bodies in effluent streams. 
Both the number of pharmaceutical compounds licensed for human use 
and their annual consumption have increased dramatically over the past 
number of years. In Ireland, the number of compounds licensed for human 
use by the Irish Medicines Board increased by 942 to approximately 6000 
from 2004 to 2005 (IMB, 2005). These compounds and their metabolites 
may potentially enter the environment. Despite this there is no monitoring 
of the level of contamination caused by such pollutants in most Irish waters 
to date.  
The following sections aim to review the current knowledge available on 
the occurrence, fate and toxicity of pharmaceutical compounds in the 
environment. 
 
1.1 Entry of Pharmaceuticals to the Environment 
 
The routes of entry and dispersal of human pharmaceuticals into the 
environment are outlined in Figure 1.1.1. Pharmaceuticals may be divided 
according to their use for examining their routes to the environment. For 
this investigation veterinary and aquaculture use of pharmaceuticals will 
not be considered although for completion are included in Figure 1.1.1. 
Pharmaceuticals used for human medicinal purposes are not completely 
metabolised in the body. Once ingested, compounds can be metabolised 
by phase I and phase II reactions (Gibson and Skett, 1986), both of which 
take place principally in the liver (Rang and Dale, 1987). Phase I 
metabolism serves to functionalise the drug. This consists of oxidation, 
 3 
 
 
Figure 1.1.1 Pharmaceutical routes of entry into the environment (adapted from Halling-Sorensen et al., 1998) 
Pharmaceutical 
formulation 
Industrial 
manufacture 
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pet treatment 
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reduction, hydrolysis, dethioacetylation or isomerisation of the parent 
compound to produce a chemically reactive group. Products of phase I 
metabolism may be more toxic than the parent compound. Phase II 
metabolism results in conjugation making a compound hydrophilic and 
easier to excrete. Both phases of metabolism change the physical and 
chemical behaviour of the parent compound and produce a metabolite with 
decreased lipid solubility thereby increasing renal excretion (Gibson and 
Skett, 1986; Rang and Dale, 1987). An overview of the metabolisation of a 
parent compound to phase I and II metabolites is shown in Figure 1.1.2. 
 
  
    
                                                                                     PHASE I METABOLITE 
 
 
 
 
PARENT COMPOUND 
 
 
 
 
 
        PHASE II METABOLITE 
 
 
Figure 1.1.2 Metabolisation of parent compound. Solid lines represent 
transformation into more water-soluble compounds, dotted lines indicate a 
reactivation of phase II metabolites (Gibson and Skett, 1986; Halling-
Sorensen et al., 1998; Daughton and Ternes, 1999).  
 
Pharmaceuticals are excreted from the body primarily in the urine 
(approximately 70%) and 30% in the faeces either as the parent 
compound or as metabolites. The percentage of metabolites formed varies 
with each compound, resulting in a cocktail of pharmaceutical compounds 
and metabolites being released to sewage (Ashton et al., 2004; Heberer, 
2002; Steur-Lauridsen et al., 2000). Conjugated forms of a compound may 
be cleaved during wastewater treatment to produce the parent compound 
thereby increasing the concentration of a compound released to the 
Oxidation, 
Reduction, 
Hydrolysis 
Conjugation with: 
Glucuronic acid   
Sulfate                
Amino acid 
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environment (Ternes and Joss, 2006). Inappropriate disposal of expired or 
unused drugs to sewage waters or in domestic waste is another potential 
source of contamination (Gros et al., 2006). 
Recent studies have reported that the efficiency of wastewater treatment 
plants for the removal of pharmaceutical compounds is low (Ternes, 1998). 
Pharmaceutical residues that pass through wastewater treatment plants 
are then released to receiving waters. Reported concentrations of selected 
compounds found in effluents and receiving water bodies are presented in 
Section 1.2. Organic hydrophobic compounds within the sewage may be 
sorbed onto sludge particles during wastewater treatment. Sorption onto 
sludge allows for the bioaccumulation of compounds (Diaz-Cruz et al., 
2003). The subsequent use of this sludge as soil fertiliser may potentially 
introduce pharmaceutical residues to ground water (Halling-Sorensen, 
1998).  
The reuse and recycling of water contaminated with wastewater effluent 
introduces a reduction in water quality. Pharmaceuticals have been 
detected in drinking water in Germany, the UK, Italy and the USA 
indicating that water reuse does occur (Jones et al., 2005). Contamination 
of drinking water supplies may occur due to drinking water plants being 
located downstream of WWTP discharge points or contamination of 
ground water by leaching from WWTP sludge spread as fertiliser.  
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1.2 Environmental Occurrence 
 
The knowledge of pharmaceutical contamination in the environment has 
increased in recent years with the development of analytical techniques 
capable of detecting trace quantities of these compounds. The most 
commonly detected compounds in environmental matrices are outlined in 
Figure 1.2.1 and include the following therapeutic classes: antibiotics, lipid 
regulators, anti-inflammatories, steroids and hormones, β-blockers, 
tranquilisers, antiepileptics, diuretics and cancer therapeutics. An overview 
of the concentration of pharmaceutical compounds, selected for this study 
(Section 2.3), detected in sewage influent and effluent streams, surface 
water, ground water and drinking water is presented in Table 1.2.1.  
 
Figure 1.2.1 Compounds most commonly detected in environmental matrices 
(Nikolaou et al., 2007). 
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Pharmaceutical  Environmental concentration (ng/L) Matrix     Reference 
Bezafibrate    27     Drinking water (Germany)  Jones et al., 2005 
     1550-7600    Sewage influent (Austria)  Clara et al., 2005 
     nd-4800    Sewage effluent (Austria)  Clara et al., 2005 
     70     Sewage effluent (Canada)  Gagné et al., 2006 
     134.3-202.7    River Lambro (Italy)   Zuccato et al., 2000 
     15.1-22.4    River Po (Italy)    Zuccato et al., 2000 
     <10-66    River Taff (Wales)   Kasprzyk-Hordern et al., 2008 
     <10-76    River Ely (Wales)   Kasprzyk-Hordern et al., 2008 
 
Caffeine    11160     Sewage effluent (Canada)  Gagné et al., 2006 
     230000   Sewage influent (Germany)  Heberer, 2002 
     180     Sewage effluent (Germany)  Heberer, 2002 
     8100     Sewage Effluent (Canada)  Verenithch et al., 2006 
     1600     Receiving water (Canada)  Verenithch et al., 2006 
 
Carbamazepine   900     Ground water (Germany)  Sacher et al., 2001 
     24 & 258    Drinking water (Canada & US)  Jones et al., 2005 
1780     Sewage influent (Germany)  Heberer 2002    
     85     Sewage effluent (Canada)  Gagné et al., 2006 
     325-1850    Sewage influent (Austria)  Clara et al., 2005 
     465-1594    Sewage effluent (Austria)  Clara et al., 2005 
     900-1200    Sewage effluent (France)  Andreozzi et al., 2003 
     3700     Sewage effluent (Germany)  Ternes, 1998 
     1780    Sewage influent (Germany)  Heberer, 2002 
     1630     Sewage effluent (Germany)  Heberer, 2002 
     1680    Sewage influent (Sweden)  Bendez et al., 2005 
     1180     Sewage effluent (Sweden)  Bendez et al., 2005 
     290     Sewage effluent (Italy)   Zuccato et al., 2005 
     180    River Lambro (Italy)   Zuccato et al., 2005 
     30     River Po (Italy)    Zuccato et al., 2005 
     360    Sewage influent (Canada)  Miao et al., 2005 
     250     Sewage effluent (Canada)  Miao et al., 2005 
     <0.5-356    River Taff (Wales)   Kasprzyk-Hordern et al., 2008 
     <0.5-684    River Ely (Wales)   Kasprzyk-Hordern et al., 2008 
Table 1.2.1 Occurrence of pharmaceuticals in the environment. nd = not detected. 
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Pharmaceutical  Environmental concentration (ng/L)  Matrix     Reference 
 
Clofibric Acid    5.3     Drinking water (Italy)   Jones et al., 2005 
70, 165, 170 & 270   Drinking water (Germany)   Jones et al., 2005 
                                                             111                                            Belfast Lough (N. Ireland)  Thomas and Hilton, 2004 
 5.77     River Po (Italy)    Calamari et al., 2003 
     3.2-5.3    Drinking water (Italy)   Zuccato et al., 2000 
     720     Sewage effluent (Germany)  Ternes, 1998 
     460     Sewage influent (Germany)  Heberer, 2002 
     480     Sewage effluent (Germany)  Heberer, 2002 
     <0.3-164    River Taff (Wales)   Kasprzyk-Hordern et al., 2008 
     <0.3-6     River Ely (Wales)   Kasprzyk-Hordern et al., 2008 
     22-248    Surface water (China)   Peng et al., 2008 
 
Clotrimazole    6-34     River Tyne (UK)   Roberts and Thomas, 2005 
 
Diclofenac    590     Ground water (Germany)  Sacher et al., 2001 
     6     Drinking water (Germany)  Jones et al., 2005 
     195       River Mersey (UK)   Thomas and Hilton, 2004 
     905-4114    Sewage influent (Austria)  Clara et al., 2005 
     780-1680    Sewage effluent (Austria)  Clara et al., 2005 
     460    Sewage effluent (Canada)  Verenithch et al., 2006 
     194                Sewage effluent (Canada)  Lishman et al., 2006 
     1600               Sewage effluent (Germany)  Ternes, 1998 
     3020                Sewage influent (Germany)  Heberer, 2002 
     2510                Sewage effluent (Germany)  Heberer, 2002 
     <0.5-85               River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <0.5-261                     River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
 
Furosemide    <6-267               River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <6-630               River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
Table 1.2.1 (continued) Occurrence of pharmaceuticals in the environment. nd = not detected. 
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Pharmaceutical  Environmental concentration (ng/L)  Matrix     Reference 
Gemfibrozil    260                           Sewage Influent (Canada)  Lee et al., 2005 
     820               Sewage Effluent (Canada)  Lee et al., 2005 
     70               Drinking water (Canada)  Jones et al., 2005 
     2100               Sewage influent (Canada)  Metcalfe et al., 2003 
     1300               Sewage effluent (Canada)  Metcalfe et al., 2003 
     110               Detroit river (Canada)    Metcalfe et al., 2003 
     70               Hamilton Harbour (Canada)  Metcalfe et al., 2003 
     840-4760                      Sewage effluent (France)  Andreozzi et al., 2003 
     710               Sewage influent (Sweden)  Bendez et al., 2005 
     180               Sewage effluent (Sweden)  Bendez et al., 2005 
     71               Sewage effluent (Canada)  Gagné et al., 2006 
     246               Sewage effluent (Canada)  Lishman et al., 2006 
     480               Sewage effluent (Canada)  Verenithch et al., 2006 
     40              Surface receiving water (Canada) Verenithch et al., 2006 
 
Ibuprofen    6770              Sewage influent (Canada)  Lee et al., 2005 
     310               Sewage effluent (Canada)  Lee et al., 2005 
     <5-41               River Rhine (Germany)   Halling-Sorensen, 1998 
     144-2370              River Tyne (UK)   Roberts and Thomas, 2006 
     3               Drinking water  (Germany)  Jones et al., 2005 
     928               River Thames  (UK)   Thomas and Hilton, 2004 
     1200-2679             Sewage influent (Austria)  Clara et al., 2005 
     22-2400              Sewage effluent (Austria)  Clara et al., 2005 
     6700              Sewage effluent (Canada)  Verenithch et al., 2006 
     9.5               Receiving water (Canada)  Verenithch et al., 2006 
     786               Sewage effluent (Canada)  Gagné et al., 2006 
     90.6-92.4              River Lambo (Italy)   Zuccato et al., 2000 
     nd-4.0               River Po (Italy)    Zuccato et al., 2000 
     380              Sewage effluent (Canada)  Lishman et al., 2006 
     <0.3-100              River Taff (Wales)   Kasprzyk-Hordern et al., 2008 
     <0.3-93              River Ely (Wales)   Kasprzyk-Hordern et al., 2008 
Table 1.2.1 (continued) Occurrence of pharmaceuticals in the environment. nd = not detected. 
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Pharmaceutical  Environmental concentration (ng/L) Matrix     Reference 
Indomethcin    280                Sewage influent (Canada)  Lee et al., 2005 
     180                Sewage effluent (Canada)  Lee et al., 2005 
     190               Sewage effluent (Canada)  Lishman et al., 2006 
 
Mefenamic Acid   34 and 104              River Mersey and Thames (UK) Thomas and Hilton, 2004 
     196               Belfast Lough  (N. Ireland)  Thomas and Hilton, 2004 
     <0.3-169                      River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <0.3-33              River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
 
Metoprolol    <0.5-11              River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <0.5-12              River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
     509-1774                        Sewage effluent (France)  Miège et al., 2006 
 
Pravastatin    117               Sewage influent (Canada)  Miao and Metcalfe, 2003 
     59               Sewage effluent (Canada)  Miao and Metcalfe, 2003 
     <60               River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <60               River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
 
Propranolol    35-107              River Tyne (UK)   Roberts and Thomas, 2005 
     56               Belfast Lough (N. Ireland)  Thomas and Hilton, 2004 
     20               River Thames (UK)    Thomas and Hilton, 2004 
     230               Sewage effluent (Germany)  Ternes, 1998 
     <0.5-40              River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <0.5-91              River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
     416-1111              Sewage effluent (France)  Miège et al., 2006 
 
Salbutamol    nd-3.1               River Lambo (Italy)    Zuccato et al., 2000 
     nd-4.6               River Po (Italy)    Zuccato et al., 2000 
     <0.5-4               River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <0.5-8               River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
Table 1.2.1 (continued) Occurrence of pharmaceuticals in the environment. nd = not detected. 
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Pharmaceutical  Environmental concentration (ng/L) Matrix     Reference 
Salicylic Acid    54000               Sewage influent (Germany)  Ternes, 1998. 
     6860                Sewage influent (Canada)  Lee et al., 2005 
     140               Sewage effluent (Canada)  Lee et al., 2005 
     2200               Sewage effluent (Canada)  Verenithch et al., 2006 
     400                Receiving water (Canada)  Verenithch et al., 2006 
     106                Sewage effluent (Canada)  Lishman et al., 2006 
     <0.3-302               River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <0.3-234               River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
     9-2098               Surface water (China)    Peng et al., 2008 
 
Sulfamethoxazole   410                Ground Water (Germany)  Sacher et al., 2001 
     49      Sewage effluent (Canada)  Gagné et al., 2006 
     nd-145    Sewage influent (Austria)  Clara et al., 2005 
     nd-91     Sewage effluent (Austria)  Clara et al., 2005 
     900     Sewage effluent (Germany)  Hirsch et al., 1999 
     <0.5-2    River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <0.5-4     River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
 
Trimethoprim    164                Sewage effluent (UK)    Hilton and Thomas, 2003 
     200                Downstream of WWTP effluent (UK) Hilton and Thomas, 2003 
     12                Streams (UK)     Ashton et al., 2004 
     28.6                Belfast Lough (N. Ireland)  Thomas and Hilton, 2004 
     46                Tyne estuary  (UK)    Thomas and Hilton, 2004 
     134                Mersey estuary (UK)    Thomas and Hilton, 2004 
     4-19                River Tyne (UK)    Roberts and Thomas, 2005 
     440                Sewage influent (Switzerland)  Göbel et al., 2005 
     400                Sewage effluent (Switzerland)  Göbel et al., 2005 
     65                Sewage effluent (Canada)  Gagné et al., 2006 
     5000                Hospital effluent (New Mexico)  Brown et al., 2006 
     4-19                River Tyne (UK)    Roberts and Thomas, 2005 
     <1.5-126               River Taff (Wales)    Kasprzyk-Hordern et al., 2008 
     <1.5-183               River Ely (Wales)    Kasprzyk-Hordern et al., 2008 
Table 1.2.1 (continued) Occurrence of pharmaceuticals in the environment. nd = not detected. 
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Numerous pharmaceuticals are ubiquitous in the environment with 
concentrations in the ng/L and low µg/L detected in wastewater streams, 
surface water and in some cases drinking water. However, the majority of 
studies on the occurrence of pharmaceuticals in the environment is 
focused on wastewater treatment plant streams, as they have been 
identified as the principal source of environmental contamination 
(Daughton and Ternes, 1999). A wide array of compounds has been 
identified in both influent and effluent streams. Bezafibrate was detected in 
effluent streams at concentrations ranging from 70 – 4800 ng/L (Clara et 
al., 2005; Gagné et al., 2006). Surface water contamination has been 
identified in four rivers in both Italy and Wales at low µg/L concentrations. 
Contamination of the drinking water supply with bezafibrate has also been 
identified in Germany (Jones et al., 2005). Carbamazepine has been 
reported in numerous studies in influent and effluent streams from 
wastewater treatment plants (Heberer, 2002; Bendez et al., 2005; Clara et 
al., 2005; Miao et al., 2005). Minimal degradation or removal was observed 
in the investigated treatment facilities. Contamination of surface and 
drinking water supplies with carbamazepine has also been identified in 
Italy, Wales, Canada and the US at low µg/L concentrations (Sacher et al., 
2001; Jones et al., 2005; Zuccato et al., 2005; Kasprzyk-Horden et al., 
2008). Clofibric acid is also frequently detected in environmental matrices 
at low mg/L concentrations. Removal of clofibric acid from wastewater 
streams was inefficient in an investigation in Berlin (Heberer, 2002). 
Although clotrimazole has not been monitored extensively, low ng/L 
concentrations were observed in the River Tyne in the UK (Roberts and 
Thomas, 2005). Diclofenac has been identified in influent and effluent 
streams from wastewater treatment facilities. Incomplete removal was 
observed in studies where both streams were monitored (Clara et al., 
2005; Heberer, 2002). Gemfibrozil has been identified in numerous 
investigations of influent and effluent streams, surface waters and drinking 
water in several countries including Canada and Sweden at low µg/L 
concentrations (Metcalfe et al., 2003; Bendez et al., 2005). Ibuprofen has  
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also been shown to be ubiquitous in the environment with contamination of 
all aquatic matrices including drinking water (Zucatto et al., 2000; Jones et 
al., 2005; Lee et al., 2005). Published removal rates of ibuprofen from 
wastewater streams are inconsistent with >90% removal reported in one 
investigation (Lee et al., 2005) while ~10% removal was observed in 
another (Clara et al., 2005). Indomethcin, mefenamic acid, metoprolol, 
pravastatin and salbutamol have been reported less frequently in the 
environment. Most reported occurrences are in surface water indicating 
that there is incomplete removal of these compounds during wastewater 
treatment (Thomas and Hilton, 2004; Lee et al., 2005; Kasprzyk-Hordern et 
al., 2008). Indomethcin was detected in both influent and effluent streams 
from eight municipal treatment plants in southern Ontario in Canada and 
removal rates of ~46% were observed (Lee et al., 2005). Removal rates for 
pravastatin were 50% in a municipal treatment plant in Peterborough 
Canada (Miao and Metcalfe, 2003).  
Sulfamethoxazole and trimethoprim have also been determined in 
influent and effluent streams, ground and surface water at ng/L and µg/L 
concentrations (Table 1.2.1). Trimethoprim was detected in hospital 
effluent at 5µg/L (Brown et al., 2006) which is more than five times the 
concentration of that detected in effluent streams from municipal plants 
(Gobel et al., 2005; Gagné et al., 2006). This highlights the importance of 
hospital effluents in final environmental loading of pharmaceuticals.  
Drinking water contamination by pharmaceuticals is not deemed to be a 
general problem. Rather, it is considered a concern associated with water 
reuse or contaminated ground water used for drinking water. The majority 
of drinking water samples analysed contains no contamination. Only a 
small number of references may be found in literature concerning the 
detection of pharmaceutical residues in drinking water, because the 
concentrations present are below the detection limits of current analytical 
techniques (Daughton and Ternes, 1999). Most reported drinking water 
contamination in Europe has been identified in Berlin, Germany. This is 
due to the high percentage (~75%) of bank filtrate (from bank filtration) and  
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contaminated groundwater used in drinking water production in Berlin 
(Heberer, 2002). Limited reports have identified contamination of Italian 
supplies with clofibric acid (Zuccato et al., 2000; Jones et al., 2005). 
Contamination of Canadian drinking water supplies with carbamazepine 
and gemfibrozil has also been reported at levels of 24ng/L and 70ng/L 
respectively (Jones et al., 2005). 
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1.3 Wastewater Treatment 
 
Traditionally wastewater treatment plants were designed to treat domestic 
waste through sedimentation processes followed by microbial degradation 
and flocculation of solids and occasionally tertiary treatment (Daughton 
and Ternes, 1999). The extent to which each phase is used greatly affects 
the efficiency of a WWTP in the removal of pharmaceutical compounds. 
For example microbial degradation plays a key role in the removal of polar 
compounds like acidic pharmaceuticals in activated sludge (Quintana et 
al., 2005).  
Treatment of municipal wastewater is a sequential process of 
mechanical, biological and chemical processes (Figure 1.3.1). Preliminary 
and primary treatments involve the mechanical removal of large debris and 
the sedimentation of suspended solids usually by gravity settling. Organic 
matter, oils, fats and greases float to the top and are also removed in the 
clarifier during primary treatment. 
 
Preliminary        Primary       Secondary Treatment         Tertiary Treatment 
Treatment      Treatment 
 
 
 
 
 
 
 
 
 
Sludge Treatment 
Figure 1.3.1 Schematic of wastewater treatment (Adapted from Swords 
WWTP schematic). 
Clarifier Aeration 
Tank 
Clarifier UV, Ozone, Activated 
carbon etc.  
Receiving 
Water 
Land 
application 
Screen 
Digestion tank Dewatering 
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Secondary treatment refers to biological treatment to reduce the 
biological oxygen demand of the wastewater. This biological treatment, 
known as activated sludge treatment, uses a diversified group of 
microorganisms ranging from bacterial genera found primarily in 
flocculated agglomerations of microbes (flocs): Zooglea, Pseudomoas, 
Bacillus, Achromobacter and Nitrosomonas to protoza Spirostomum and 
Amoeba proteus and rotifers: Philodina spp. and Notommata spp.. The 
make up of activated sludge systems is variable and often plant specific as 
there is internal selection within each system. Factors influencing organism 
selection within a system are outlined in Figure 1.3.2. The final stage of 
secondary treatment is clarification of the sludge. Biomass is allowed to 
settle out of solution to yield a clarified effluent. The final effluent is then 
discharged into a receiving water body or subjected to tertiary treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.2 Organism selection for activated sludge treatment (Henze, 
2002). 
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The purpose of tertiary treatment is to improve the quality of effluent from 
wastewater facilities. Tertiary treatments include both physical and 
chemical methods such as precipitation, ozonation and ultraviolet 
exposure for the removal of excess nutrients and suspended material and 
disinfection. Ultraviolet exposure may also assist the removal of residual 
organics from effluent streams (Gebhardt and Schröder, 2007; Canonica 
et al., 2008).  
1.4 Pharmaceuticals in Wastewater Treatment Plants 
 
Pharmaceutical substances designed for human medicinal purposes are 
predominantly hydrophilic in nature in order to improve uptake by the 
human body. Sorption to activated sludge, as discussed in Section 1.3, is 
a method of micropollutant removal within wastewater treatment plants. 
Compounds with a low solid-liquid partitioning coefficient exhibit low or 
negligible sorption within a WWTP. This implies that a high proportion of 
hydrophilic pharmaceutical compounds remain in the liquid phase in 
WWTP systems (Ternes and Joss, 2006). Increasing instances of 
pharmaceutical compounds in aquatic matrices confirms the incomplete 
removal of these pollutants in many WWTPs (Giger, et al., 2003). 
Limited data on the behaviour and removal of pharmaceuticals as they 
pass through a WWTP are available. Consequently, it is difficult to 
determine degradation and removal efficiencies of WWTPs. Removal 
efficiencies are determined by measuring and comparing the influent and 
effluent concentrations. These vary significantly between WWTPs due to 
differences in the treatment technology, retention times and also weather 
conditions (Fent et al., 2006). The partitioning of compounds between solid 
and liquid phases of wastewater, degradation to lower molecular weight 
compounds and compound transformation to conjugated forms, which may 
later be hydrolysed to reform the parent compound, are all factors that 
affect removal efficiencies. Removal rates of German WWTPs near 
Frankfurt/Main were investigated in 1996 and 1997 (Ternes, 1998). Thirty-
two drug residues and five metabolites were analysed. Elimination rates 
ranged from seven percent to ninety-nine percent. For example, 
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carbamazepine showed the lowest removal rate at seven percent while 
others (fenofibrate, meclofenamic acid, tolfenamic acid, salicylic acid and 
acetaminophen) were undetectable in effluents despite initial 
concentrations of up to 54µg/L. A similar investigation of WWTPs in Rio de 
Janeiro in Brazil showed removal rates from thirty-four (clofibric acid) to 
eighty-three (indomethcin) percent (Stumpf et al., 1999). In this study the 
performance of both activated sludge and biological filters as secondary 
treatments were compared. Activated sludge had a marginally higher 
percentage removal for the nine pharmaceutical compounds investigated. 
The percentage removal ranged from 6% to 71% for the biological filter 
while 34% to 83% was the range for the activated sludge treatment. 
Comparable studies in Berlin, Frankfurt and Finland were also published in 
2002 and 2005 respectively (Herberer, 2002; Lindqvist et al., 2005). 
Removal rates (Table 1.4.1) were similar to those reported for the 
activated sludge plant in Rio de Janeiro. For example, removal rates of 
ibuprofen were greater than 75% in the activated sludge treatments 
studied while the biological filter was less effective for the removal of 
ibuprofen (22%). Similarly, removal rates of clofibric acid, gemfibrozil, 
diclofenac, fenofibric acid, bezafibrate and naproxen were comparable in 
the activated sludge treatments at Frankfurt/Main and Rio de Janeiro. The 
removal rates determined for indomethcin in the biological filter in Rio de 
Janeiro were comparable with those observed for the activated sludge 
treatment at Rio de Janeiro and Frankfurt/Main. 
Removal of pharmaceuticals due to sorption to organic material in the 
wastewater will be removed during primary treatment. The potential for 
compounds to partition to organic material is usually described by the 
octanol/water partitioning coefficient (Kow) (Keenan, et al., 2008). The Kow 
refers to absorption of compounds due to hydrophobic interactions. 
Therefore, it would be expected that compounds with a high partitioning 
coefficient would be expected to sorb to solids while compounds with low 
partitioning coefficients would be expected to remain in the liquid phase. 
Pharmaceuticals can also be removed due to adsorption which refers to 
the removal of a compound due to electrostatic interactions which can be 
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determined by the dissociation constant (pKa) (Carballa et al., 2005). 
Remaining in the liquid phase aids the transportation of pharmaceutical 
compounds through WWTPs and in the release into the environment. The 
organic carbon coefficient (Koc) refers to the concentration sorbed to 
organic carbon and that dissolved in water (Keenan et al., 2008). When 
available, the Koc can be used to predict the partitioning of compounds 
between solid and liquid phases. The low pKa and high Kow of 
carbamazepine suggest that it could be removed by sorption to sludge but 
poor removal efficiencies were observed in the activated sludge plants at 
Frankfurt/Main (Ternes, 1998) and Berlin (Heberer, 2002). However, due 
to the high variability and multiplicity of input parameters the specific 
partitioning of a compound can only accurately be determined by analysing 
its concentration both the solid and liquid portion of a sample. The solid-
water distribution coefficient for a particular sample can then be defined as 
L
SK d =  where, S is the concentration in the solid phase and L is the 
concentration in the liquid phase (Carballa et al., 2005).  
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Compound  Frankfurt/Main Rio de Janeiro Rio de Janeiro  Berlin         Finland 
   Activated sludge Biological Filter Activated sludge  Activated sludge Activated sludge 
Clofibric Acid  51   15   34           0         - 
Ibuprofen   90   22   75         -a         78-100 
Gemfibrozil   69   16   46         -a         - 
Ketoprofen   -   48   69         24         51-100 
Phenazone   33   -   -         44         - 
Diclofenac   69     9   75         17           9-60 
Fenofibric Acid  64     6   45         -         - 
Bezafibrate   83   27   50         -         11-100 
Indomethcin  75   71   83           0         - 
Naproxen   66   15   78         82         55-98 
Carbamazepine     7   -   -           8         - 
Table 1.4.1 Percentage removal of pharmaceutical compounds reported in WWTPs in four different studies (Ternes, 1998; 
Stumpf et al., 1999; Heberer, 2002; Lindqvist et al., 2005). 
a
 Compounds were detected in effluent samples but not in influent. 
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1.5 Ecotoxicological Effects 
 
Most published literature to date has dealt with the occurrence of 
pharmaceuticals in the environment, in wastewater treatment streams and 
receiving waters, rather than the ecotoxicological effects resulting from 
these pollutants. However, pharmaceuticals are continually infused into the 
environment allowing them to exert a similar threat to the environment as 
persistent pollutants (Jones et al., 2002). Moreover, the possibility of 
emerging strains of bacteria resistant to drugs due to constant exposure to 
low concentrations is a public health concern (Renew and Huang, 2004; 
Yang and Carlson, 2004). 
WWTPs receive industrial and domestic waste streams containing low 
concentrations of pharmaceutical compounds and metabolites. Continual 
exposure to low-level residues selects for organisms resistant to the 
compounds present. This results in a reservoir of resistant bacteria. 
Studies on Klebsiellae strains isolated from treatment plants have shown 
that ninety percent show insensitivity to ampicillin and six percent show 
multiple resistance (Hirsh et al., 1999). 
Toxicity testing endeavours to predict the possible adverse effects of 
exposure to chemicals (Meyer, 2003). Toxicity data for compounds 
analysed in this study (Section 2.3) are summarised in Table 1.5.1. The 
effect concentration for 50% of the test population (EC50) and the lethal 
concentration causing death in 50% of the test population (LC50) are 
presented for several test organisms. Toxicity concentrations were in the 
mg/L range indicating that the low µg/L concentrations reported in aqueous 
samples should not impart a negative effect. However, the effects of each 
compound are analysed individually thus toxicity testing does not 
accurately reflect the fact that organisms are exposed to a cocktail of these 
compounds in the environment. Exposure to compounds with similar 
modes of action increases the potential of synergistic effects (Jones et al., 
2002). Two concepts, concentration addition and independent action have 
been used in recent years to estimate the risk associated with exposure to 
a complex mixtures of compounds. For example, the toxicity of clofibric 
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acid and carbamazepine in acute Daphnia studies were measured both 
individually and as a mixture. It was found that the combined toxicity was in 
agreement with the concept of concentration addition showing an increase 
in toxicity. Similarly, a mixture of ibuprofen and diclofenac showed a higher 
toxicity than expected from the individual toxicities (Cleuvers, 2003).  
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 Daphnid Algae 
 
Fish 
Hydra 
attenuata 
Synechococcus 
leopoliensis 
Cyclotella 
meneghiniana 
Vibrio 
fischeri 
Lemna 
gibba 
Thamnocephalus 
platyurus 
Brachionus 
calyciflorus 
Bezafibrate 25 1 18 1 5.3 
1
  
      
Caffeine 46 1 46 1 805 
1
 LC50 >100 2 
      
Carbamazepine 111 1 70 1 101 
1
 15.52 2 33.6 3 31.6 3 LC50 >813   
   
 LC50 29.4 2       
Clofibric acid 293 1 192 1 53 
1
  
      
Diclofenac 5057 1 2911 1 532 
1
  
  13.5 3    
 
22.4 3 
 
  
  0.01 5    
 
22.4 4 
 
  
      
Furosemide LC500.6 10       LC50 70.6 10 2.5 10 
Gemfibrozil 6 
1
 4 1 0.9 1 1.2 2   0.03 5    
 
   LC50 22.36 2       
Ibuprofen 38 
1
 26 1 5 1 1.65 2   0.02 5    
 
   LC50 22.4 2       
Indomethcin 26 1 18 1 3.9 
1
  
      
Mefenamic acid 0.428 9* 
 
  
      
Metoprolol 8 1 14 1 116 
1
  
      
Propranolol 2.3 1 5.5 1 
29.5 
1
 
 
0.67 3      
 
1.6 8   
 
      
Salicylic acid 59 1 48 1 
1.28 
1
 
 
      
Sulfamethoxazole 4.5 1 51 1 890 
1
 >100 2 0.03 3  >84 3 0.08 7   
Trimethoprim 4.8 1 2.6 1 795 
1
 LC50 >100 2 
      >1.0 6     
Table 1.5.1 Toxicity data for compounds analysed in this study. 
* PNEC data. 1 Sanderson et al., 2003 ECOSAR data; 2 Quinn et al., 2008; 3 Ferrari et al., 2004; 4 Ferrari et al., 2003; 5 la Farre et al., 2001; 6 Crane et al., 
2006; 7 Brian et al., 2004; 8 Huggett, et al., 2002; 9 Jones et al., 2002; 10 Isidori et al., 2006. 
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Environmental risk assessments (ERA) are required for pharmaceutical 
compounds prior to licensing in Europe to assess the potential risk of a 
compound to the environment. The ERA process is outlined in Figure 
1.5.1. The first phase of the ERA requires that the predicted environmental 
concentration (PEC) of a compound be calculated. If this is less than 
0.01µg/L the compound is considered to be unlikely to present a risk to the 
environment. The PEC (mg/L) is calculated using equation 1.  
 
 
    
DV
FMDD
PEC pen
×
×
=    (1) 
 
Where:  MDD is the maximum daily dose in mg per person per day,  
Fpen is the percentage of market penetration (percentage of  
population being treated with the drug),  
V is the amount of wastewater in litres per person per day  
D is the dilution factor 
 
 
If the PEC is equal to or greater than 0.01µg/L then phase two analysis is 
required. Phase two involves evaluating the PEC/PNEC ratio. Predicted no 
effect concentration (PNEC) is estimated by assessing toxicity data on 
algae, Daphnia sp. or fish and determining the no observed effect 
concentration (NOEC) to which an assessment factor (AF) is applied to 
account for any variation in experimental parameters. If the PEC/PNEC 
ratio is less than one, it means that the predicted environmental 
concentration is less than that which will have an environmental effect and 
is therefore not likely to cause a risk to the environment. If this value is >1, 
further toxicity considerations are required and safety measures may need 
to be included in the product labelling (EMEC, 2006).  
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Will product enter the environment? 
    PEC > 0.01µg/L 
    
   
 
                                                                           
  Crude environmental effect analysis 
   Initial PEC/PNEC > 1? 
 
 
 
                          Detailed relevant characterisation of potential risks 
        Refined PEC/PNEC >1? 
 
 
 
 Guidance for precautionary and safety measures  
  
Figure 1.5.1 Environmental risk assessment scheme for human medicinal 
products (Knacker, 2002). 
 
 
There has been a number of studies to determine the environmental risk 
posed by compounds frequently found in the environment. PECs for 
twenty-five pharmaceuticals prescribed in England predicted that twelve 
compounds would have an environmental concentration above 1µg/L while 
all would have a concentration above 0.01µg/L. Only four compounds 
(amoxicillin, paracetamol, mefenamic acid and oxytetracycline) had a 
PEC/PNEC ratio above one (Jones et al., 2002). However, the calculated 
PECs are higher than the actual environmental concentrations reported 
(Table 1.5.2). Another such investigation compared PECs with measured 
environmental concentrations (MEC) and found that the PECs over-
estimated the actual environmental concentration in all cases but both 
PECs and MECs were above the regulatory guide for PEC (0.01µg/L). 
YES 
NO 
YES 
NO 
Is there a risk identified 
Product is unlikely to   
          present an    
    environmental risk 
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MEC/PNEC ratios were calculated for eleven compounds including 
analgesics, anti-inflamatories, antibiotics and anti-depressants, and were 
found to be less than one implying that they posed no potential 
environmental risk (Ashton et al., 2004). While amoxycillin had a 
PEC:PNEC ratio of 588.02 indicating a potential environmental threat there 
was no amoxycillin measured in environmental samples. 
 
Compound  PEC  PNEC  PEC:PNEC MEC 
    µg/L  µg/L  Ratio  µg/L 
 
Amoxycillin  2.19  0.0037 588.02 nd 
      250  0.01 
 
Paracetamol  11.96  9.2  1.29  ~0.5 
      136  0.09 
      29  0.41 
 
Mefenamic Acid 0.47  0.638  0.74  0.196 
    0.44  0.428  1.03 
 
Oxytetracycline 0.83  0.23  3.60  0.1 
      4.5  0.18 
Table 1.5.2 PEC, PNEC and MEC concentrations (Ashton et al., 2004). 
nd = not detected
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1.6 Thesis Scope 
 
Wastewater Treatment facilities 
 
The wastewater treatment facilities selected in this study are located at 
Ringsend, Swords and Leixlip. Figure 1.6.1 shows the location of the 
facilities and the corresponding discharge locations of each of the plants. 
The characteristics of each plant are shown in Table 1.6.1. Ringsend is the 
largest of the three facilities and it is located in Dublin Bay. The effluent 
from the plant is combined with the effluent from a power station prior to 
entry into Dublin Bay at the mouth of the River Liffey. The plant has a 
population equivalence of approximately 1.7 million. Leixlip wastewater 
treatment plant is located on the river Liffey. The plant has a total 
population equivalence of 90,000. While, there are two separate streams in 
the plant (industrial and domestic) only the domestic stream with a 
population equivalence of 29,000 is used for this study. The industrial 
stream has a population equivalence of 61,000 and was not considered for 
this study. The effluent from this plant is discharged directly into the river 
Liffey east of Leixlip village. Swords treatment plant is located in north 
Dublin. It has a population equivalence of 50,000. The effluent from this 
plant is discharged into the Broadmeadow estuary north of Dublin Bay. 
 28 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.1 Location of selected wastewater treatment facilities and discharge locations (DP – Discharge point)  
Source: Google Earth 
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 Ringsend Leixlip Swords 
Population 
Equivalence 
1.7 million 29,000 50,000 
Mean Flow (m3/d) 525,875 11,032 10,842 
Treatment Activated sludge Activated sludge Activated sludge 
Additional treatment UV (Summer 
months) 
- - 
Discharge location Liffey Estuary/Dublin 
Bay 
River Liffey Broadmeadow 
Estuary 
Table 1.6.1 Wastewater treatment plant characteristics (Personal at Ringsend, 
Leixlip and Swords wastewater treatment facilities). 
 
 
Selection of Analytical Techniques 
Liquid chromatography tandem mass spectrometry (LC-MS) and gas 
chromatography tandem mass spectrometry (GC-MS) are analytical 
techniques involving the coupling of two individual techniques resulting in 
methods allowing for the separation, quantification and identification of 
complex mixtures of compounds. GC-MS has been used for the 
determination of pesticides and such pollutants in complex environmental 
samples. However, for GC-MS analysis analytes must be thermostable 
and volatile. Almost all pharmaceutically active compounds are either polar 
or thermally unstable molecules rendering them unsuitable for direct 
analysis by GC-MS. Chemical derivatisation is required prior to analysis for 
such compounds to enhance their volatility (Ahuja, 2001). Quantification 
may prove difficult if derivatisation is included in sample preparation as 
incomplete derivatisation and the formation of multiple products is 
possible. LC-MS overcomes this problem as it is suitable for analysis of a 
wider range of compounds including those that are thermolabile or exhibit 
polarity. The extensive use of LC-MS technology for the detection of 
pharmaceutical residues in environmental samples has proven the 
suitability of this technique.  
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LC-MS combines high performance liquid chromatography (HPLC) with 
mass spectrometry (MS) via a suitable interface. LC serves to separate a 
complex mixture of compounds while MS determines molecular ions. The 
resulting retention times and molecular masses allow for the identification 
and quantitation of compounds.  
LC involves the partitioning of analytes between a liquid mobile phase 
and a solid stationary phase. The composition of the mobile solvent phase 
remains constant for isocratic chromatography while gradient elution 
chromatography can be achieved by using differing concentrations of 
solvent solutions (Hancock and Sparrow, 1984).  
LC can be run in both normal and reverse phase. In normal phase 
chromatography, separations are generally performed between a non-
polar organic mobile phase and a silica stationary phase. In reverse phase 
LC the separation occurs due to a non-polar stationary phase and a polar 
mobile phase. The separation of analytes in reversed phase 
chromatography depends on the hydrophobic interactions between the 
sample and the mobile phase (Fallon et al., 1987). The molecular size of 
the molecule may play a role in the separation. Small polar molecules are 
eluted more rapidly than large non-polar molecules. In normal phase LC 
the size of the molecule does not determine the separation of analytes 
(Smith, 1988). Reverse phase LC is most frequently used for the detection 
of pharmaceutical compounds in aqueous matrices. 
Electrospray ionisation mass spectrometry is commonly used for the 
identification of multi-class pharmaceutical compounds in environmental 
samples (Gros et al., 2006). Electrospray ionisation is the interface used to 
couple LC with the MS and involves the transfer of ions from the liquid 
phase to the gas phase and also as a link between the atmospheric 
pressure of the LC and the high vacuum MS. The sample is passed 
through a metal capillary to which a voltage has been applied. An electric 
field is obtained between the capillary and a counter-electrode. Charged 
droplets produced at the end of the capillary are pulled towards the 
oppositely charged counter electrode due to both the potential difference 
and the pressure gradient. The droplets are reduced in size in the 
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ionisation chamber due to solvent evaporation. As the droplet size reduced 
the Rayleigh limit is reached, where the forces of repulsion of ions in the 
droplet are greater than the surface tension of the liquid, and a coulombic 
explosion occurs. The process is repeated until gas phase ions are 
formed. The ions are then sampled and focused using an electrostatic 
lensing system into the ion trap. The ions are trapped in a stable trajectory. 
A varying radiofrequency (RF) voltage is applied to a ring electrode and 
ions become unstable and are directed towards the detector with 
increasing mass to charge (m/z) ratio. The resulting plot or mass spectrum 
is the relative abundance of each charged species against the m/z ratio. 
The mass analyser operates under vacuum to prevent or minimise the 
collision between the ions formed (Ardrey, 2003; Hoffmann and Stroobant, 
2002; Pease, 1980). 
 
The concentration of pharmaceutical compounds in environmental 
matrices is usually very low, in the ng/L range. For this reason a pre-
concentration step is necessary prior to analysis. Solid phase extraction 
(SPE) is a method which is widely used for sample preconcentration and 
sample clean up. SPE involves the sorption of an analyte, from a sample, 
to a stationary solid phase followed by recovery of the analyte by elution 
usually in an organic phase. Therefore, SPE is used for the isolation, 
concentration and medium transfer of trace analytes in environmental 
aqueous samples (Huck and Bonn, 2000; Leon-Gonzalez et al., 2000; 
Poole, 2002).   
There are four main steps involved in SPE; conditioning, adsorption, 
washing and elution (Huck and Bonn, 2000). 
 
1. Conditioning 
 
Conditioning is the pre-treatment of the sorbent material. This is 
usually accomplished by passing a solvent through the sorbent 
material. This renders the surface more hydrophilic and therefore 
more compatible with the sample solution.  
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2. Adsorption 
 
The liquid sample is passed through the SPE sorbent material and 
analytes are retained on the sorbent material.  
3. Washing 
 
This step allows for the removal of interfering compounds eg. salts 
without eluting the desired analyte. This is often achieved using a 
water wash. The solid phase is then dried usually under a stream 
of nitrogen to remove excess water. 
4. Elution 
 
Adsorbed analytes are removed/eluted from the solid matrix. This 
elution is commonly accomplished using an organic solvent 
however, a gas stream may be used to thermally desorb analytes.  
Research Objectives 
There is a lack of published research on the level of environmental 
contamination due to pharmaceutical compounds in Ireland. Research to 
date in this area has determined environmental concentrations in other 
countries. However, seasonal variation and the effects seasonal climate 
change may have on pharmaceutical concentrations have not been 
investigated.  
 
The main aims of this project were to: 
• Develop a multi-residue method for the detection and quantitation 
of selected pharmaceuticals in the WWTPs. 
• Establish the level of pharmaceuticals in the influent and effluent 
of three WWTPs in the greater Dublin region. 
• Establish the efficiency of selected wastewater treatment plants in 
treating contaminated water 
• Ascertain any seasonal variation in pharmaceutical occurrence 
• Establish if the environmental concentrations found have any 
potential toxicological effect.  
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• Investigate the potential use of artificial neural networks for the 
prediction the effluent concentration of pharmaceuticals. 
 
Twenty compounds were chosen for this study. Occurrence of 
compounds in the environment and on the list of the top one hundred 
prescribed compounds were both considered (HSE, 2004). A wide range 
of compounds including anti-inflammatories, analgesics, antibiotics, anti-
fungal agents, β-blockers, β2 agonists and statins is included in the chosen 
analytes. The chosen compounds are listed in Table 2.3.1.  
A twelve-month sampling regime was designed to provide a database 
from which to determine any seasonal relationship. As a wastewater 
treatment plant is a controlled system there is a limited number of 
influencing environmental factors, mainly rainfall and sunlight. The 
efficiency of each wastewater treatment plant for the removal of selected 
analytes was investigated. Monthly influent and corresponding effluent 
samples provide the relevant data to evaluate removal efficiencies. 
Published toxicological data are used to compare measured analyte 
concentrations with potential toxicological effects (Table 1.5.1 page 22). 
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2.0 Materials and Methods 
 
2.1 Materials 
 
Methanol, acetonitrile, acetonitrile with 0.1% ammonium acetate and water 
with 0.1% ammonium acetate were purchased from Sigma-Aldrich, Dublin, 
Ireland and were of HPLC grade or LC-MS grade.  Dichlorodimethylsilane 
and toluene, HPLC grade, were also purchased from Sigma-Aldrich, 
Dublin, Ireland. Pharmaceuticals for investigation included trimethoprim 
(≥98%), caffeine (≥99%) were purchased from Fluka (Buchs, Switzerland), 
bezafibrate (≥98%), flurbiprofen (≥99%), indomethcin (≥99%), ibuprofen 
sodium salt (≥98%), mefenamic acid (≥99%), gemfibrozil (≥99%), 
salbutamol (≥98%), sulfamethoxazole (≥98%), furosemide (≥98%), 
carbamazepine (≥98%), nimesulide (≥98%) obtained from Sigma 
(Steinham, Germany) and salicylic acid (≥99%), propranolol hydrochloride 
(≥98%), clofibric acid (≥98%), diclofenac sodium salt (≥98%) and 
clotrimazole (≥98%) purchased from Aldrich (Steinham, Germany). Strata–
X solid phase extraction cartridges were purchased from Phenomenex, 
United Kingdom.  
1000mg/L stock solutions of each analyte were prepared in methanol 
and stored at 40C in the dark for optimum stability. Stock solutions were 
replaced periodically. Working standards were prepared by dilution using 
methanol from these stock solutions.  
 
2.2 Glassware Preparation 
 
All glassware used was silanised by rinsing thoroughly with a 10% (v/v) 
solution of dichlorodimethylsilane in toluene followed by two toluene rinses 
and then two methanol rinses. This was to prevent any pharmaceutical 
residue from adsorbing to the glassware. 
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2.3 Choice of Analytes 
 
A range of analytes, representative of commonly used pharmaceuticals in 
human medicine, including analgesics, anti-inflammatories, β-blockers, 
anti-fungal agents and anti-convulsants was chosen for analysis. Selected 
analytes include both acidic and basic compounds with pKa values ranging 
from 1.8 to 14.0. The frequency of detection in environmental aqueous 
samples reported in published literature and their presence on the list of 
the top one hundred prescribed compounds in Ireland in 2004 were also 
considered in the selection of analytes (HSE, 2004). The twenty selected 
analytes along with their respective pKa values and chemical structures are 
presented in Table 2.3.1. 
 
2.4 Sewage Samples 
 
Amber glass bottles were used for the collection of 2.5 litres of sewage 
samples on site. All bottles were silanised prior to sampling. Three sewage 
treatment plants with six sampling sites were included in the sampling 
regime. Twenty-four hour composite samples were collected monthly from 
each site and transported to the laboratory. Auto samplers at each location 
were used to collect periodic aliquots. The aliquots were pooled and a two 
litre representative sample taken. The samples were adjusted to pH 4 
using concentrated sulphuric acid and filtered through Whatman GF/C 
glass fibre filters to remove suspended solids on arrival.  Samples were 
stored at 40C until analysed. All samples were analysed within forty-eight 
hours.  
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Compound Therapeutic Class Molecular 
Weight 
pKa logP LogKOW Reference 
Bezafibrate Anti-lipemic 361 3.6 4.2 -0.4 Bibic et al., 2007 
Weigel et al., 2004 
Caffeine CNS stimulant 194 14.0 -0.07 -0.1 Bones et al., 2006 
Weigel et al., 2004 
Carbamazepine Anti-convulsant 236 13.9 2.45 2.7 Bones et al., 2006 
Weigel et al., 2004 
Clofibric Acid Anti-lipemic 214 3.2 2.58 -1.3 Scheytt et al., 2005 
Weigel et al., 2004 
Clotrimazole Anti-fungal agent 344 6.1 3.5 4.1 Bones et al., 2006 
OSPAR, 2005 
Diclofenac Anti-inflammatory 318 4.2 1.13 -0.4 Bibic et al., 2006 
Weigel et al., 2004 
Flurbiprofen Anti-inflammatory 244 4.3 4.16 - Bibic et al., 2006 
Furosemide Loop diuretic 330 3.9 2.03 2.0 Bones et al., 2006 
Gemfibrozil Lipid regulating agent 250 4.8 3.09 4.7 Brown et al., 2007 
Ibuprofen Anti-inflammatory 206 4.3 3.97 0.3 Bibic et al., 2007 
Weigel et al., 2004 
Table 2.3.1 Therapeutic class, molecular weight, pKa, logP and LogKow values of target pharmaceuticals 
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Compound Therapeutic Class Molecular 
Weight 
pKa logP LogKOW Reference 
Indomethcin Anti-inflammatory 357 4.5 4.27 - Bones et al., 2006 
Mefenamic Acid Anti-inflammatory 241 4.2 5.12 5.1 Bones et al., 2006 
Metoprolol Beta blocker 267 9.4 1.95 0.6 Bibic et al., 2007 
Weigel et al., 2004 
Nimesulide Anti-inflammatory 308 6.5 3.08  Alves et al., 2007 
Pravastatin Cholesterol lowering 
statin 
446 4.7 -  Kobayashi et al., 2003 
Propranolol 
Hydrochloride 
Beta blocker 295 9.5 3.48 1.9 Bibic et al., 2007 
Weigel et al., 2004 
Salbutamol Beta2 agonist 239 9.2 - 0.01 Yamini et al., 2006 
Salicylic Acid Analgesic/Aspirin 
metabolite 
138 3.5 2.36 1.2 Bones et al., 2006 
Sulfamethoxazole Antibiotic 253 1.8, 5.6 6.89 0.48 Bibic et al., 2007 
Zwiener, 2007 
Trimethoprim Antibacterial agent 290 3.2 0.91  Bibic et al., 2007 
Table 2.3.1 Therapeutic class, molecular weight, pKa, logP and LogKow values of target pharmaceuticals 
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2.5 Method Development 
 
Solid phase extraction (SPE) cartridges were used to pre-concentrate 
samples. A selection of six cartridges (Supelco Supelclean C8 and C18, 
Phenomenex Strata-X, Waters Oasis HLB, Varian Focus and Merck 
LiChrolut EN) was initially investigated for recovery of ten analytes. The 
ten selected compounds were representative of the full pKa range. Prior to 
extraction the solid phase cartridges were washed with three column 
volumes (6 mL) of methanol followed by three column volumes of water to 
prepare for the sample matrix. A one litre sample that was spiked to a 
concentration of 5µg/L of the ten analytes was passed through each of the 
solid phase extraction cartridge using vacuum. Cartridges were washed 
with one column volume of water after the addition of sample, dried for 
thirty minutes using vacuum and then eluted with ten millilitres of methanol. 
Figure 2.5.1 outlines the main steps in the SPE protocol. After elution, 
samples were dried under nitrogen, re-suspended in methanol to a volume 
of one millilitre and analysed by high performance liquid chromatography. 
 
 
Figure 2.5.1 Schematic of SPE method 
 
A Varian inert 9012 solvent delivery system, a Dynamax automatic sample 
injector model AI-200 and a Varian 9050 variable path length UV-VIS 
detector were used for the development of the standard HPLC separation. 
Resolution was achieved using a 150 x 4.6 mm end-capped Sunfire C18 
Matrix 
components 
Analyte 
6 mL water 
wash 
10 mL 
methanol 
eluent 
Elute Wash Adsorption 
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3.5µm reversed phase HPLC column (Waters, Ireland). A series of 
different mobile phases including methanol and acetonitrile as the organic 
phase and water with an ammonium acetate (pH 6.4) or formic acid (pH 
2.8) buffer was investigated to determine the optimum. A 50µL injection 
volume and flow rate of 1.0 mL/min were employed and the absorbance 
was monitored using UV. The optimum wavelength (225nm) was 
determined in preliminary studies using scanning spectrometry. The 
optimised method was then transferred to a narrower bore Sunfire C18 
column, 150 x 2.1 mm. The flowrate was adjusted accordingly to 0.3 
mL/min and the injection volume was reduced to 10 µL. The optimised 
gradient is shown in Table 2.5.1. 
 
Time %A %B 
0 100 0 
5 100 0 
25 0 100 
45 0 100 
Table 2.5.1 HPLC Gradient. A: 80:20 (v/v water/acetonitrile) with 0.1% 
ammonium acetate. B: 20:80 (v/v water/acetonitrile) with 0.1% ammonium 
acetate. 
 
A Bruker Daltonics Esquire~LC ion trap MS with an electrospray ionisation 
interface at atmospheric pressure was used for MS analysis. MS 
conditions were optimised separately. Standard solutions of each analyte 
were directly infused, using a Cole Parmer 74900 series syringe pump 
(Cole Parmer, Vernon Hills, IL, USA), into the mass spectrometer at a 
flowrate of 300µL/h. MS conditions were automatically optimised using 
Bruker Esquire software for each analyte. An average of the recorded 
parameters was used as the final focusing and ionisation parameters. The 
precursor peak with the greatest intensity was fragmented using tandem 
MS and the most abundant product ion was chosen for monitoring of the 
tandem MS signal. 
 40 
The completed LC-ESI-MS/MS method for analysis used an Agilent 1100 
LC system (Agilent Technologies, Palo Alto, CA, USA) coupled to a Bruker 
Daltonics Esquire~LC ion trap MS with an electrospray ionisation interface 
at atmospheric pressure (Bruker Daltonics, Coventry, UK). A Waters 
Sunfire, narrow bore, 150 x 2.1 mm C18 column with 3.5µm particle size 
was used for separation. A flowrate of 0.3mL/min and an injection volume 
of 10 µL were employed. The LC-ESI-MS/MS system was controlled using 
Agilent Chemstation version A.06.01 and Bruker Daltonics Esquire Control 
version 6.08. Bruker Daltonics Data analysis software was used for data 
analysis. An overview of the method development is shown in Figure 2.5.2. 
 
Direct infusion of 
standards
Sampling 
programme
Validate method 
using actual 
samples
Gradient Elution
Mobile phase
Investigate various 
SPE cartridges
Optimise wavelength 
using scanning 
spectrometry
Concentration of 
analyte in WW
Mass 
spectrometry 
optimisation
HPLC 
Optimisation
Solid Phase 
extraction 
optimisation
SPE – LC-MS
Optimum 
parameters
Optimum 
wavelength
Buffer Type
Organic Phase
Run time 
and gradient
LOD and LOQ
Linearity
% RSD
 
Figure 2.5.2 Overview of SPE-LC-MS/MS method development and 
validation  
 
2.6 Method Validation 
 
The SPE recovery of analytes was determined in WWTP influent and 
effluent sample matrices. Samples were spiked to a concentration of 5µg/L 
with a mixed standard of ten analytes and extracted using Strata-X 
cartridges in triplicate. The concentration recovered was compared to the 
initial spiking concentration. Blank samples (unspiked influent and effluent 
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samples) were also extracted to determine the concentration of analytes 
present in the sample before spiking and any background concentration 
was included in the calculation.  
The precision, linearity and sensitivity of the overall SPE-LC-ESI-MS/MS 
method was investigated. Method precision was defined in terms of 
repeatability and reproducibility. Six replicate samples were spiked to a 
concentration of 1.40µg/L of each analyte using a mixed standard solution 
containing 2mg/L (of each of twenty analytes). Influent and effluent 
samples were similarly spiked to give six concentrations of each analyte 
ranging from 0.60 – 2.80 µg/L and analysed. Linearity was determined 
between the peak area and concentration using regression analysis. 
Sensitivity of the method (limits of detection (LOD) and limits of 
quantitation (LOQ)) was determined in both influent and effluent sample 
matrix. The LOD was calculated as the analyte concentration that gave a 
response equal to three times the signal to noise ratio. The LOQ was 
defined as the analyte concentration to give a response equal to ten times 
the signal to noise ratio (Ahuja and Scypinski, 2001). Both were calculated 
based on repeated injections (n=6) of a 1mg/L standard. 
 
2.7 Matrix Effects 
 
The effect of matrix components on the LC-MS/MS analysis was 
investigated. Two studies were undertaken to determine the level of signal 
suppression or enhancement due to matrix components. Suppression or 
enhancement was determined as the change in the intensity and peak 
area for individual analytes. 
 
2.7.1 Addition Post Extraction 
 
Influent and effluent samples were extracted using SPE as per the method 
developed for sample analysis. Each of the target pharmaceuticals (Table 
2.3.1) was then added to the extract to yield a compound concentration of 
2µg/L. The samples were analysed using the LC-MS/MS method outlined 
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in Section 2.5 and compared to a 2 µg/L standard solution. The difference 
in response between the two samples is used to quantify the extent of 
matrix effects on the compound under the given analytical conditions. 
Results are reported in Section 3.3.1. 
 
2.7.2 Post Column Infusion 
 
Both influent and effluent extracts were injected on to the LC column to 
achieve separation of the matrix components. A 0.5mg/L standard solution 
of individual compounds (nimesulide, mefenamic acid, trimethoprim and 
carbamazepine) was continually infused into the flow post column and pre 
electrospray interface (Figure 2.7.1). The analyte signal was monitored for 
the duration of the run. This allowed the effects of matrix components over 
the 45min run time to be analysed. Blank samples (sample extracts) were 
analysed in all cases to determine any interference from trace levels 
already present in the sample. The results obtained are reported in Section 
3.3.2. 
 
 
Figure 2.7.1 Post column infusion experimental setup. 
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2.7.3 Standard Additions 
 
A mixed standard solution containing 5 mg/L of each of the twenty analytes 
was prepared and used for standard additions in monthly samples. 
Depending on the volume of sample collected, each sample was divided 
into three or four aliquots of 500 mL. One sample was extracted and 
analysed without any addition and the remaining samples were spiked with 
increasing concentrations of the analyte standard solution to yield a 
concentration of 1, 2 and 3 µg/L in the samples. The samples were then 
extracted and analysed using the LC-MS/MS method outlined in Section 
2.5. The peak area counts for each analyte were determined using Bruker 
Daltonics EsquireLC 4.5 Data Analysis software version 3.0. Regression 
analysis between the peak area counts and concentration was used to 
calculate the concentration of each analyte in the raw sample. The 
variation of analyte signal suppression between influent and effluent 
matrices could be determined by comparison of the same addition in both 
matrices. Also, the standard additions method identified the complete 
suppression of analyte signal due to matrix effects in certain cases.  
 
2.8 Metal Analysis 
 
The presence of metals in wastewater streams was investigated to assess 
the potential for metal related interference in analysis of samples. ICP-AES 
analysis was completed on influent and effluent samples from the three 
wastewater treatment plants. As this facility was not available the analysis 
was performed by an INAB (Irish National Accreditation Board) accredited 
laboratory, TMS Environment Ltd. Results are presented in Section 3.4. 
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2.9 Surfactant Analysis 
 
The effect of the surfactant linear alkyl benzene sulphonate (LAS) (Figure 
2.9.1) on LC-MS/MS analysis was investigated. LAS is an anionic 
surfactant commonly used in detergents and cleaners (Clara et al., 2007). 
An almost complete removal (>99%) of LAS during wastewater treatment 
has been reported previously (Temmink and Klapwijk, 2004). LAS is a 
highly polar compound which can be concentrated on SPE cartridges 
(Schröder, 1999) and is known to impair electrospray ionisation signals of 
various compounds (Ishihama et al., 2000). For these reasons the effect of 
LAS on the signal suppression of four compounds (nimesulide, mefenamic 
acid, carbamazepine and trimethoprim) was investigated. 
Analyte standard solutions were prepared and analysed as above. The 
same concentration of analytes was also prepared in a 2% LAS solution 
and analysed. The results were compared with respect to signal intensity, 
peak shape and retention time. Results are presented in Section 3.5.  
 
SO3Na
n m
 
Figure 2.9.1. LAS structure 
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3.0 Results 
 
3.1 Method Development 
 
Sample pre-treatment 
 
Analyte recoveries from six commercially available solid phase extraction 
cartridges were investigated initially. The mechanism of retention for both 
C8 and C18 cartridges is the same as that of reverse phase 
chromatography - non-specific hydrophobic interactions between the 
analytes and the hydrocarbon chain of the stationary phase. Strata-X has 
both a hydrophobic and hydrophilic entity and is suitable for the 
preconcentration of both polar and non-polar analytes (Figure 3.1.1). Oasis 
HLB also has hydrophilic and hydrophobic entities and is suitable for both 
polar and non-polar analyte recovery. The Focus cartridge produced by 
Varian is also suitable for the concentration of polar and non-polar 
compounds. It incorporates four retention mechanisms: proton donor, 
proton acceptor, polar and hydrophobic. Merck LiChrolut EN is a mixed 
polarity copolymer sorbent and is suitable for the preconcentration of both 
polar and non-polar compounds. Recoveries in excess of 100% were 
found for some analytes. This may be a result of variances in the matrix as 
a real sample matrix was used for this investigation (Section 3.3). Strata-X 
yielded the highest average recovery for the analytes investigated and was 
used for further investigations (Table 3.1.1). An extraction pH of 4 was 
used as it had been shown previously to give optimum recovery for similar 
compounds (Bones et al., 2006). 
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Figure 3.1.1 Structure of Strata-X (Phenomenex) 
 
 
 
 C8 C18 Strata-X HLB Focus LiChrolut 
Bezafibrate 99.3 65.0 110.3 110.2 97.3 71.7 
Clofibric acid 93.7 77.3 94.5 90.5 61.7 61.5 
Diclofenac 75.3 43.4 76.6 71.1 59.4 42.1 
Flurbiprofen 137.8 89.5 130.5 119.8 104.7 87.5 
Gemfibrozil 90.3 58.5 87.5 84.1 60.7 37.3 
Ibuprofen 75.9 59.8 73.6 76.2 56.9 49.9 
Indomethcin 117.7 64.1 123.4 112.7 102.9 49.0 
Mefenamic acid 101.7 62.7 101.2 92.0 84.9 45.9 
Salicylic acid 5.7 16.3 107.8 90.5 21.3 38.9 
 
Table 3.1.1 Percentage recovery of analytes from six SPE cartridges. 
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LC-ESI-MS/MS 
 
LC-MS/MS was the method of choice for this work due to its applicability to 
a wide range of compounds including polar, thermo-labile compounds. 
Also, MS allows for the positive identification and quantification of 
compounds. 
A Waters Sunfire C18, 150 x 2.1 mm column with a 3.5 µm particle size 
was used for chromatographic separation of selected analytes. Separation 
was monitored by UV at 270nm which was determined as the optimum 
using scanning spectrometry. A series of different mobile phases including 
methanol and acetonitrile as the organic phase and water with an 
ammonium acetate or formic acid buffer was investigated. A simple 
gradient of 20-80% acetonitrile with 0.1% ammonium acetate in both the 
aqueous (pH 6.4) and organic phase gave sufficient separation of the 20 
analytes for detection. 
Over the course of the separation two analytes (nimesulide and 
flurbiprofen) were found to co-elute at 22.3 and 22.5 mins. Caffeine and 
trimethoprim also have close retention times of 2.0 and 2.1 mins. Due to 
the complexity of the sample matrix and presence of matrix components 
UV detection was not sensitive enough for the quantitation of analytes and 
therefore MS detection was used. The separation and detection of 
analytes using this method are illustrated in Figure 3.1.2 a and b.  
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Figure 3.1.2a Chromatograms of a 5µg/mL standard in influent matrix 
analysed using negative ionisation  
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Figure 3.1.2a (continued) Chromatograms of a 5µg/mL standard in 
influent matrix analysed using negative ionisation  
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Figure 3.1.2a (continued) Chromatograms of a 5µg/mL standard in 
influent matrix analysed using negative ionisation  
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Figure 3.1.2b Chromatograms of a 5µg/mL standard in influent matrix 
analysed using positive ionisation. 
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Figure 3.1.2b (continued). Chromatograms of a 5µg/mL standard in 
influent matrix analysed using positive ionisation. 
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September 2006 to February 2007, were analysed using only parent ions 
and the results are reported in Appendix A. To improve the identification of 
analytes, monitoring of product ions was included in the method. Product 
ions were determined by fragmentation of the parent ion under MS/MS 
Carbamazepine 
Clotrimazole 
Propranolol 
O
OH
N
H
CH3
CH3
HCl
 
N
NH2O
 
N
N
Cl
 
 53 
conditions. Parent and product ions are listed in Table 3.1.2. Optimum MS 
parameters for the analytes are tabulated in Tables 3.1.3 and 3.1.4. No 
product ions were observed for salicylic acid, flurbiprofen or 
sulfamethoxazole in negative mode ionisation. Caffeine also yielded no 
fragmentation ion in positive mode ionisation. Monitoring of these 
compounds was consequently restricted to the precursor ions.  
 
 Rt Parent ion Product ion 
Negative ionisation 
   
Salicylic acid 3.0 137 - 
Sulfamethoxazole 9.7 252 - 
Furosemide 13.0 329 285 
Pravastatin 13.6 423 321 
Clofibric acid 14.1 213 127 
Bezafibrate 17.3 360 274 
Nimesulide 22.3 307 229 
Flurbiprofen 22.5 199 - 
Diclofenac 23.5 250 214 
Indomethcin 23.7 213 297 
Ibuprofen 24.5 205 159 
Mefenamic acid 26.5 240 196 
Gemfibrozil 27.5 249 121 
Positive ionisation 
   
Salbutamol 0.8/1.5 240 195 
Caffeine 2.0 194 - 
Trimethoprim 2.1 291 230 
Metoprolol 4.0 268 159 
Propranolol 11.0 260 183 
Carbamazepine 14.5 237 194 
Clotrimazole 23.1 277 165 
Table 3.1.2 Retention times (Rt) and ions for LC-MS/MS monitoring. 
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Salicylic  
acid 
Clofibric 
acid 
Bezafibrate Flurbiprofen Diclofenac Indomethcin 
Capillary 4500 4500 4500 4500 4500 4500 
End plate offset 626 592 1085 500 1200 649 
Skim 1 15 46 15 28 32 42 
Skim 2 5.4 13.5 4.7 8.1 6.4 5.9 
Lens 1 2.0 4.3 3.0 1.3 1.5 6.1 
Lens 2 41.5 50.7 39.2 30.0 30.0 81.6 
Cap Exit Offset 53.3 50.0 50.0 50.0 50.0 68.0 
Octopole 1.1 1.6 1.0 1.8 1.9 1.0 
Octopole ∆ 1.9 2.2 1.4 2.1 2.4 1.5 
Octopole RF 127.9 50.0 300.0 181.1 230.3 189.3 
Trap drive 29.4 37.9 33.3 35.9 34.7 28.9 
Table 3.1.3 Optimum parameters for analytes analysed in negative ESI mode.  
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Ibuprofen Mefenamic 
acid 
Nimesulide Furosemide Sulfamethoxazole Gemfibrozil 
Capillary 4500 4500 4500 4500 4500 4500 
End plate offset 649 695 672.1 867.2 500 500 
Skim 1 15.0 15.0 19.2 15.0 15.0 26.1 
Skim 2 5.9 4.2 5.7 4.7 4.9 6.9 
Lens 1 2.7 2.3 1.4 2.4 1.3 1.5 
Lens 2 36.9 46.1 30.0 42.6 30.0 30.0 
Cap Exit Offset 69.7 51.6 54.9 51.6 50.0 50.0 
Octopole 1.9 1.0 1.9 2.0 1.5 1.9 
Octopole ∆ 2.3 1.4 1.7 1.8 1.5 2.5 
Octopole RF 160.7 222.1 181.2 254.9 164.8 201.6 
Trap drive 30.3 29.7 39.4 39.4 34.9 33.8 
Table 3.1.3 (Continued) Optimum parameters for analytes analysed in negative ESI mode.  
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Clotrimazole Propranolol Metoprolol Carbamazepine Trimethoprim Caffeine Salbutamol 
Capillary 4500 4500 4500 4500 4500 4500 4500 
End plate offset 707 672 752 534 718 500 741 
Skim 1 15 15 94 15 26 15 15 
Skim 2 6.4 6.9 4.7 6.6 5.9 6.2 6.4 
Lens 1 0.8 3.8 1.7 1.0 1.5 0.9 3.2 
Lens 2 30.0 59.8 30.0 30.0 30.0 38.1 51.8 
Cap Exit Offset 73.0 63.1 66.4 71.3 76.2 51.6 50.0 
Octopole 3.0 3.2 2.8 2.9 2.6 2.6 2.7 
Octopole ∆ 2.0 2.3 2.0 2.1 1.9 1.5 1.5 
Octopole RF 205.7 209.8 173.0 160.7 160.7 173.0 185.3 
Trap drive 38.4 38.0 36.1 35.9 34.7 33.5 36.3 
Table 3.1.4 Optimum parameters for analytes analysed in positive ESI mode. 
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3.2 Method Validation 
 
The SPE-LC-MS/MS method was validated in both influent and effluent 
sample matrices and validation data are presented in Tables 3.2.1. and 
3.2.2. Linearity was determined using regression analysis between the 
area ratios and concentration. Correlations of R2>0.9, with the exception 
of ibuprofen, were obtained over a concentration range of 0.60-2.90µg/L. 
Limits of detection and quantitation (LOD and LOQ) were defined as the 
concentration yielding a signal to noise ratio of 3:1 and 10:1 respectively.  
As seen in Table 3.2.1 the LOD ranged from 0.002 – 0.855 µg/L in 
influent and 0.001 – 0.743µg/L in effluent samples. LOQ ranged from 
0.005 – 2.850 µg/L in influent samples and 0.003 – 2.478 µg/L in effluent 
samples. The precision of the overall method was determined from six 
replicates of low-level spiked samples (1.40µg/L). Precision varied by 
less than 10% in most cases. High variability (34.7%) was observed for 
reproducibility of ibuprofen while repeatability varied by only 9% as 
shown in Table 3.2.2. Bezafibrate, clofibric acid, flurbiprofen, furosemide, 
gemfibrozil, indomethcin, metoprolol, pravastatin and salicylic acid had 
percentage reproducibility values above 10%. With the exception of 
caffeine (10.2%) repeatability was below 10% for all analytes. Variability 
in precision has been shown to increase with increased complexity in a 
matrix (Bones et al., 2006). Six samples were used to determine the 
precision of the overall method. As there is sample to sample variation in 
matrix components a precision of ~10% in results was seen as 
acceptable in this study. 
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Linearity (R2) LOD (µg/L) LOQ (µg/L)  
 
 Influent Effluent Influent Effluent 
Bezafibrate 0.9854 0.033 0.050 0.112 0.150 
Caffeine 0.9894 0.280 0.138 0.934 0.460 
Carbamazepine 0.9951 0.010 0.004 0.034 0.013 
Clofibric acid 0.9813 0.222 0.335 0.740 1.118 
Clotrimazole 0.9932 0.010 0.004 0.034 0.013 
Diclofenac 0.9972 0.855 0.743 2.850 2.478 
Flurbiprofen 0.9907 0.743 0.489 2.478 1.629 
Furosemide 0.9205 0.094 0.109 0.313 0.365 
Gemfibrozil 0.9749 0.026 0.010 0.086 0.032 
Ibuprofen 0.8558 0.228 - 0.760 - 
Indomethcin 0.9712 0.263 0.283 0.877 0.792 
Mefenamic acid 0.9222 0.020 0.004 0.060 0.013 
Metoprolol 0.9831 0.633 0.097 2.111 0.324 
Nimesulide 0.9655 0.002 0.001 0.005 0.003 
Pravastatin 0.9371 0.072 0.047 0.239 0.156 
Propranolol 0.9618 0.007 0.017 0.022 0.057 
Salbutamol 0.9558 0.008 0.155 0.027 0.518 
Salicylic acid 0.9864 0.028 0.115 0.093 0.383 
Sulfamethoxazole 0.9799 0.072 0.166 0.241 0.553 
Trimethoprim 0.9126 0.171 0.020 0.570 0.067 
Table 3.2.1 Linearity and detection and quantitation limits of the method. 
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 % RSD 
 Reproducibility Repeatability 
Bezafibrate 13.7 3.5 
Caffeine 4.7 10.2 
Carbamazepine 3.6 2.6 
Clofibric acid 14.4 4.9 
Clotrimazole 6.3 4.4 
Diclofenac 5.8 3.4 
Flurbiprofen 13.5 1.1 
Furosemide 18.2 0.1 
Gemfibrozil 17.7 3.7 
Ibuprofen 34.7 9.0 
Indomethcin 11.4 2.5 
Mefenamic acid 5.3 0.2 
Metoprolol 14.5 2.4 
Nimesulide 8.1 5.0 
Pravastatin 13.9 4.7 
Propranolol 6.6 5.3 
Salbutamol 8.4 2.0 
Salicylic acid 15.6 1.4 
Sulfamethoxazole 8.0 1.0 
Trimethoprim 8.7 4.0 
 
Table 3.2.2 Validation data for precision of overall method 
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3.3 Matrix Effects 
 
The negative effect of matrix components on electrospray mass 
spectrometry has been identified previously in environmental and clinical 
samples (Petrović et al., 2005; Taylor, 2005). The effect of influent and 
effluent matrix components on the LC-MS/MS method used in this study 
was investigated using two methods - 1) addition post extraction and 2) 
post column infusion. 
 
3.3.1 Addition Post Extraction  
 
The analyte response from a standard solution of selected compounds 
was compared to that obtained from the same concentration of the 
compounds in influent and effluent SPE extract. The results of these 
experiments are presented in Table 3.3.1.  
Analyte signal suppression was observed in both influent and effluent 
matrices. Suppression in influent samples was in general greater than that 
observed in effluent samples. For example, the signal for clotrimazole was 
suppressed by 25.8% in the effluent matrix with a corresponding 
suppression of 43.9% in the influent matrix. Similarly, the suppression 
observed for nimesulide reduced significantly from influent to effluent 
where the suppression in effluent matrices was <5% while in the influent it 
was 18.5%. Ibuprofen was most affected by the presence of matrix 
components with >70% suppression observed in both influent and effluent 
matrices. Trimethoprim and gemfibrozil both had significant levels of 
suppression in influent samples (32.8% and 45.6%) while that in effluent 
samples was <5%. Carbamazepine, mefenamic acid, nimesulide and 
trimethoprim (in bold in Table 3.3.1) were selected for further investigations 
on matrix components as they represent a range of retention times and 
ionisation modes.  
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 % Ion Suppression 
 Influent Effluent 
Bezafibrate <5 <5 
Caffeine 28.3 5.4 
Carbamazepine 37.7 23.0 
Clofibric acid 15.6 29.7 
Clotrimazole 43.9 25.8 
Diclofenac 23.7 27.7 
Flurbiprofen 60.5 37.2 
Furosemide -48.7 10.7 
Gemfibrozil 45.6 <5 
Ibuprofen 77.6 72.0 
Indomethcin 11.8 44.2 
Mefenamic acid <5 25.8 
Metoprolol 52.8 39.1 
Nimesulide 18.5 <5 
Pravastatin 15.6 27.5 
Propranolol 88.7 32.7 
Salbutamol <5 77.0 
Salicylic acid <5 56.3 
Sulfamethoxazole -60.3 33.8 
Trimethoprim 38.2 <5 
 
Table 3.3.1 % Ion suppression due to matrix components. 
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3.3.2 Post Column Infusion 
 
These four compounds (carbamazepine, mefenamic acid, nimesulide and 
trimethoprim), two detected using positive mode ionisation and two using 
negative mode ionisation and with varying retention times were chosen as 
representatives for this investigation. The results are presented in Figures 
3.3.1, 3.3.2, 3.3.4, 3.3.5. In general signal suppression was greater in 
influent samples. Signals for nimesulide and mefenamic acid were almost 
completely suppressed for the duration of the run with the addition of 
influent matrix components and at the retention times of 22.3 and 26.5 
minutes respectively. The signal suppression observed with effluent 
samples was less than that in influent samples. There was minimal 
suppression for the majority of the run time with short time frames showing 
complete suppression. This indicates a significant removal of suppressing 
compounds during treatment. Similarly the signal intensity for 
carbamazepine (Rt = 14.5 min) and trimethoprim (Rt = 2.1 min) in the 
influent matrix was suppressed to a greater degree than that observed in 
the effluent matrix.  
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Figure 3.3.1 Effect of signal suppression on nimesulide (negative mode). 
Brown line: Infused nimesulide standard (0.5mg/L); Blue line: Infused nimesulide 
standard (0.5mg/L) + extracted influent sample; Green line: Infused nimesulide 
standard (0.5mg/L) + extracted effluent sample.  
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Figure 3.3.2 Effect of signal suppression on mefenamic acid (negative 
mode). 
Brown line: Infused mefenamic acid standard (0.5mg/L); Blue line: Infused 
mefenamic acid standard (0.5mg/L) + extracted influent sample; Green line: 
Infused mefenamic acid standard (0.5mg/L) + extracted effluent sample. 
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Figure 3.3.3 Effect of signal suppression on Carbamazepine (Positive 
mode). 
Brown line: Infused carbamazepine standard (0.5mg/L); Blue line: Infused 
carbamazepine standard (0.5mg/L) + extracted influent sample; Green line: 
Infused carbamazepine standard (0.5mg/L) + extracted effluent sample. 
 
 
 66 
 
 
Figure 3.3.4 Effect of signal suppression on trimethoprim (Positive mode). 
Brown line: Infused trimethoprim standard (0.5mg/L); Blue line: Infused 
trimethoprim standard (0.5mg/L) + extracted influent sample; Green line: Infused 
trimethoprim standard (0.5mg/L) + extracted effluent sample. 
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3.3.3 Standard Additions 
 
To allow for accurate quantification of compounds in influent and effluent 
samples, an internal standard or standard additions can be used to correct 
any analyte signal suppression or enhancement. In this study standard 
additions were used because in addition to allowing analyte quantification 
they further illustrate the effect of signal suppression. Graphical 
representation of the data from the three plants in November 2007 was 
chosen to illustrate the method of standard additions.  
Figures 3.3.5 – 3.3.9 show data from the Leixlip plant. The linear graphs 
(Figures 3.3.5 – 3.3.8) highlight the >0.9 regression achieved from 
standard additions in both influent and effluent samples. Quantification of 
individual compounds was possible using these graphs. Also, the effect of 
matrix suppression is evident. For example, the peak area counts for the 
standard additions of carbamazepine were ~15% greater in effluent 
samples than influent samples (Figure 3.3.5). Figure 3.3.6 also highlights a 
difference in analyte response between influent and effluent samples. The 
peak area count for the 2 µg/L addition in the influent sample is ~1750000 
while the equivalent in the effluent sample is 100% greater at ~3500000. 
Trimethoprim was detected and quantified in the effluent sample collected 
from Leixlip in November 2007 (Figure 3.3.8a), however, it was not 
detected in the corresponding influent. Figure 3.3.9 shows the extracted 
ion chromatograms for trimethoprim from the influent sample and three 
subsequent standard additions. It is clear that trimethoprim with a retention 
time of 2.1 minutes is absent from all chromatograms which clearly 
demonstrates that complete signal inhibition occurred.  
The November data from the Swords plant are presented in Figures 
3.3.10 - 3.3.18. Again, linear plots show the high degree of linearity 
obtained for individual compounds detected and quantified. Peak areas 
obtained for the standard additions in effluent samples are greater than 
those observed for the same addition in influent samples for clotrimazole, 
carbamazepine and nimesulide (Figures 3.3.10, 3.3.11 and 3.3.12). Linear 
plots showing the linearity of the additions in effluent samples where the 
compound is absent in the raw sample are also included (Figures 3.3.11 
 68 
and 3.3.12). For example, carbamazepine and nimesulide were not 
detected in the influent sample from Swords in November but the linearity 
of the additions was > 0.9. Figures 3.3.15 – 3.3.18 are extracted ion 
chromatograms illustrating the suppression of the analyte signal in influent 
samples.  
Data from the Ringsend November sample are presented in Figures 
3.3.19 – 3.3.25. Good linearity was obtained for compounds detected in 
influent and effluent matrices and the peak area counts for the same 
standard additions were generally greater in effluent samples than influent 
samples. For example, peak area counts for additions of carbamazepine 
were ~25% greater in effluent samples than in influent samples. The 
extracted ion chromatograms in Figures 3.3.24 and 3.3.25 show the 
absence of signal in influent samples for furosemide and mefenamic acid 
while both compounds were quantifiable in corresponding effluent 
samples.  
The standard additions method highlighted complete suppression of 
flurbiprofen, mefenamic acid, diclofenac, clofibric acid, sulfamethoxazole 
and ibuprofen in influent samples from the WWTPs. Indomethcin and 
salbutamol were also completely suppressed in influent matrix from the 
Swords plant. Suppression of the indomethcin signal was ~50% and ~70% 
in the Leixlip and Ringsend treatment plants respectively and salbutamol 
was suppressed by ~ 90% in both Leixlip and Ringsend influent samples. 
No analyte was completely suppressed in effluent matrices. Other analyte 
signals were significantly suppressed in influent samples compared to 
effluent signals. The signal for metoprolol was suppressed by ~50% in 
Leixlip influent samples, ~40% in Ringsend samples and ~80% in Swords 
samples. Signal suppression of bezafibrate varied from ~30% to ~70% in 
the three plants. The amount of signal suppression varied both between 
WWTPs and also between samples. Therefore it is important that standard 
additions are used in every sample for quantification of analytes.  
 
 69 
 
y = 757348x + 166515
R2 = 0.9954
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
Concentration (µg/L)
Pe
a
k 
A
re
a 
Co
u
n
ts
a) Influent 
y = 779199x + 376364
R2 = 0.9795
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
Concentration (µg/L)
Pe
a
k 
A
re
a 
Co
u
n
ts
 
b) Effluent 
Figure 3.3.5 Carbamazepine: standard additions in influent (a) and 
effluent (b) samples from Leixlip, November 2007. 
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Figure 3.3.6 Clotrimazole: standard additions in influent (a) and effluent 
(b) samples from Leixlip, November 2007. 
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Figure 3.3.7 Nimesulide: standard additions in influent (a) and effluent (b) 
samples from Leixlip, November 2007. 
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Figure 3.3.8 Trimethoprim (a) and Furosemide (b): standard addition in 
effluent sample from Leixlip, November 2007. 
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a) Trimethoprim: Influent 
 
 
b) Trimethoprim: Influent + 2µg/L standard 
 
c) Trimethoprim: Influent + 3 µg/L standard 
 
 
d) Trimethoprim: Influent + 4 µg/L standard 
 
Figure 3.3.9 Chromatograms to illustrate the absence of signal for standard addition of trimethoprim in influent sample (Leixlip 
November 2007). Arrow indicates Rt for trimethoprim. 
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Figure 3.3.10 Clotrimazole: standard addition in influent (a) and effluent 
(b) samples from Swords, November 2007. 
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Figure 3.3.11 Carbamazepine: standard addition in influent (a) and 
effluent (b) samples from Swords, November 2007. 
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Figure 3.3.12 Nimesulide: standard addition in influent (a) and effluent (b) 
samples from Swords, November 2007. 
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a) Furosemide 
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Figure 3.3.13 Furosemide (a) and trimethoprim (b): standard additions in 
effluent samples from Swords, November 2007. 
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a) Mefenamic acid 
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b) Propranolol 
Figure 3.3.14 Mefenamic acid (a) and propranolol (b): standard additions 
in effluent samples from Swords, November 2007. 
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a) Furosemide: Influent 
 
b) Furosemide: Influent + 2µg/L standard 
 
c) Furosemide: Influent + 3µg/L standard 
 
d) Furosemide: Influent + 4µg/L standard 
Figure 3.3.15 Chromatograms illustrating the absence of signal for standard additions of furosemide in influent samples. 
(Swords November 2007). Arrow indicates Rt for furosemide. 
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a) Trimethoprim: Influent 
 
 b) Trimethoprim: Influent+ 2 µg/L standard 
 
c) Trimethoprim: Influent + 3 µg/L standard 
 
 d) Trimethoprim: Influent + 4 µg/L standard 
Figure 3.3.16 Chromatograms illustrating the absence of signal for standard additions of trimethoprim in influent samples. 
(Swords November 2007). Arrow indicates Rt for trimethoprim. 
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a) Mefenamic acid: Influent 
 
b) Mefenamic acid: Influent + 2 µg/L standard 
 
c) Mefenamic acid: Influent + 3 µg/L standard 
 
d) Mefenamic acid: Influent + 4 µg/L standard 
Figure 3.3.17 Chromatograms illustrating the absence of signal for standard additions of mefenamic acid in influent samples. 
(Swords November 2007). Arrow indicates Rt for mefenamic acid. 
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a) Propranolol: Influent 
 
b) Propranolol: Influent + 2 µg/L standard 
 
c) Propranolol: Influent + 3 µg/L standard 
 
d) Propranolol: Influent + 4 µg/L standard 
 
Figure 3.3.18 Chromatograms illustrating the absence of signal for standard additions of propranolol in influent samples. 
(Swords November 2007). Arrow indicates Rt for propranolol. 
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Figure 3.3.19 Carbamazepine: standard additions in influent (a) and 
effluent (b) samples from Ringsend, November 2007. 
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Figure 3.3.20 Metoprolol: standard additions in influent (a) and effluent (b) 
samples from Ringsend, November 2007. 
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Figure 3.3.21 Clotrimazole: standard additions in influent (a) and effluent 
(b) samples from Ringsend, November 2007.  
 86 
y = 53821x + 47709
R2 = 0.9634
0
50000
100000
150000
200000
250000
0 0.5 1 1.5 2 2.5 3 3.5
Concentration (µg/L)
Pe
a
k 
A
re
a 
Co
u
n
ts
 
a) Influent 
y = 646246x + 825247
R2 = 0.9985
0
500000
1000000
1500000
2000000
2500000
3000000
0 0.5 1 1.5 2 2.5 3 3.5
Concentration (µg/L)
Pe
a
k 
A
re
a
 
Co
u
n
t
 b) Effluent 
Figure 3.3.22 Nimesulide: standard additions in influent (a) and effluent (b) 
samples from Ringsend, November 2007. 
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Figure 3.3.23 Furosemide (a) and mefenamic acid (b): standard additions 
in effluent samples from Ringsend, November 2007. 
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a) Furosemide: Influent 
 
 
b) Furosemide: Influent + 2µg/L standard 
 
c) Furosemide: Influent + 3 µg/L standard 
 
 
Figure 3.3.24 Chromatograms illustrating the absence of 
signal for standard additions of furosemide in influent 
samples (Ringsend, November 2007). Arrow indicates Rt 
for furosemide. 
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a) Mefenamic acid: Influent 
 
 
b) Mefenamic acid: Influent + 2 µg/L 
 
c) Mefenamic acid: Influent + 3 µg/L 
 
Figure 3.3.25 Chromatograms illustrating the absence of 
signal for standard additions of mefenamic acid in 
influent samples (Ringsend, November 2007). Arrow 
indicates Rt for mefenamic acid. 
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3.4 Metal Analysis 
 
ICP-AES metal analysis results from TMS Environment Ltd. are presented 
in Table 3.4.1. Influent and corresponding effluent samples from the three 
plants were analysed for twelve metals. The concentrations were very low 
in both influent and effluent samples. The only metals present above 
detection limits were chromium, copper, iron, manganese and lead.  
 
 
 
Influent (mg/L) 
 
Effluent (mg/L) 
 
 
Silver 
Swords 
<0.005 
Leixlip 
<0.005 
Ringsend 
<0.005 
Swords 
<0.005 
Leixlip 
<0.005 
Ringsend 
<0.005 
Arsenic <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 
Cadmium <0.005 <0.005 <0.005 <0.005 <0.005 <0.005 
Chromium 0.0059 0.0059 0.0072 0.0066 0.0052 <0.005 
Copper 0.061 0.074 <0.05 <0.05 <0.05 <0.05 
Iron 0.054 0.083 0.43 0.014 0.025 0.086 
Mercury <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
Manganese 0.005 0.084 0.081 0.057 0.041 0.036 
Nickel <0.02 <0.02 <0.02 <0.02 <0.02 <0.02 
Lead 0.026 <0.01 0.025 0.024 <0.01 0.022 
Tin <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
Zinc <0.01 <0.01 <0.01 0.029 0.029 <0.01 
Table 3.4.1 Metal concentrations detected in influent and effluent samples 
at three wastewater treatment plants 
 
3.5 Surfactant Analysis 
 
The effect of linear alkyl benzene sulphonate on the LC-MS/MS method 
was investigated in this study. The experimental design was similar to the 
that used for addition post extraction in that a standard solution was 
compared to the same concentration in a LAS solution. The results are 
presented in Figures 3.5.1 and 3.5.2. The analysis of nimesulide was 
significantly affected by the presence of LAS. The signal was completely 
suppressed and no analyte peak was observed (Figure 3.5.1b). The 
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retention time of mefenamic acid was altered in the presence of LAS by 
approximately one minute but the peak area count was unaffected (Figure 
3.5.1d). The retention of trimethoprim was altered with the addition of the 
surfactant. The peak broadened and was eluted over three minutes and 
separated to give multiple peaks (Figure 3.5.2b). The analyte response for 
carbamazepine was not affected by the addition of the surfactant (Figure 
3.5.2c and d). The effect of LAS on signal suppression does not appear to 
be influenced by the mode of ionisation but rather is compound specific.  
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a) Nimesulide Standard 
 
 
b) Nimesulide Standard + LAS 
 
c) Mefenamic acid standard 
 
 
d) Mefenamic acid + LAS 
Figure 3.5.1 Effect of LAS on analysis of nimesulide and mefenamic acid in negative mode ionisation.  
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a) Trimethoprim standard 
 
 
b) Trimethoprim standard + LAS 
 
c) Carbamazepine standard 
 
 
d) Carbamazepine standard + LAS 
 
Figure 3.5.2 Effect of LAS on analysis of trimethoprim and carbamazepine in positive mode ionisation. 
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3.6 Monthly Sampling  
 
Twenty four hour composite influent and effluent samples were collected 
from each of the three wastewater treatment facilities each month from 
July 2007 to June 2008. Samples were analysed using the SPE-LC-
MS/MS method outlined in Section 2.6. Results are presented in Tables 
3.6.1, 3.6.2 and 3.6.3. Operational data from the three treatment plants, on 
the day of sampling and corresponding weather data are also included in 
the tables. Thirteen of the selected compounds were present at 
concentrations above the LOD in samples collected from the Swords 
treatment plant. Carbamazepine and clotrimazole had the highest 
frequency of occurrence. Apparent concentrations of both these 
compounds exhibited higher values in effluent streams. Bezafibrate (2 
samples), caffeine (4 samples), diclofenac (1 sample), metoprolol (2 
samples), pravastatin (4 samples), propranolol (1 sample) and salicylic 
acid (2 samples) had limited occurrence in samples collected from Swords. 
Trimethoprim was identified and quantified in five samples during the 
sampling period. Influent and corresponding effluent concentrations were 
found only in March 2008. The rate of removal for trimethoprim was 94.6%. 
Similarly, influent and corresponding effluent concentrations of furosemide 
and nimesulide were observed in only one month (January 2008 and June 
2008 respectively). No removal of furosemide was observed while removal 
of nimesulide was greater than 99%. Mefenamic acid was found only in 
effluent samples collected from the Swords plant.  
 In the samples collected from the Leixlip treatment plant, thirteen of the 
selected compounds were found. Clotrimazole and carbamazepine were 
present most often in the samples. In general the concentration of these 
two compounds in effluent samples was greater than that observed in 
corresponding influent samples. A reduction in carbamazepine 
concentration during treatment was observed once in May 2008, while a 
reduction in clotrimazole concentration occurred in both August 2007 and 
May 2008. Caffeine was present in influent samples with no corresponding 
effluent concentration with the exception of July 2007. Diclofenac (4 
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samples), gemfibrozil (5 samples), mefenamic acid (4 samples), 
metoprolol (3 samples), pravastatin (3 samples), propranolol (2 samples), 
and salicylic acid (2 samples) occurred infrequently during the sampling 
period. Furosemide and trimethoprim occurred more frequently. However, 
no pattern of removal or increase in concentration was apparent.  
 Thirteen compounds were also found to be present in samples collected 
from the Ringsend treatment facility and again carbamazepine and 
clotrimazole were detected more often than the other eleven compounds.  
The concentrations of carbamazepine and clotrimazole were frequently 
higher in effluent than influent samples. Bezafibrate, diclofenac, salicylic 
acid, propranolol and pravastatin were detected only on one or two 
occasions. Mefenamic acid was detected in four effluent samples and 
never in corresponding influent samples. The occurrence of furosemide 
was inconsistent in influent or effluent samples. In July 2007 and March 
2008 furosemide was detected in both influent and effluent samples and 
removal varied from 34% to 95%. Metoprolol was detected in four months 
samples (July, August and November 2007 and June 2008). The 
concentration apparently increased during treatment. There was no trend 
in the pattern of occurrence for either nimesulide or trimethoprim. Both 
compounds were detected in effluent samples and not in corresponding 
influent samples. However, nimesulide was detected in both influent and 
corresponding effluent samples in March 2008. 
 
 In total fourteen of the twenty analytes were found in wastewater 
samples. Caffeine, carbamazepine, clotrimazole, diclofenac, furosemide, 
mefenamic acid, metoprolol, nimesulide, pravastatin, propranolol, salicylic 
acid and trimethoprim were detected in the three treatment plants. 
Bezafibrate was found in the Swords and Ringsend plants but absent in 
samples collected from the Leixlip plant while gemfibrozil was found only in 
samples from the Leixlip plant.  
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 Aug 2007 Sept 2007 Oct 2007 Nov 2007 Dec 2007 
 Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff 
Bezafibrate <0.03 <0.05 7.25 <0.15 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 
Caffeine <0.93 <0.14 <0.28 <0.14 34.9 <0.46 <0.93 <0.14 <0.28 <0.14 
Carbamazepine <0.03 0.26 <0.01 0.25 0.1 1.09 <0.01 0.25 <0.03 0.35 
Clotrimazole <0.01 <0.01 <0.01 <0.01 0.54 0.45 0.90 1.20 <0.03 0.33 
Diclofenac Sup <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 
Furosemide <0.09 <0.37 Sup <0.37 <0.09 <0.37 <0.09 0.50 Sup <0.37 
Mefenamic acid Sup 0.53 Sup 0.20 Sup <0.13 Sup 0.25 Sup 0.57 
Metoprolol 2.57 <0.10 Sup <0.10 <0.63 <0.10 <0.63 <0.10 Sup <0.10 
Nimesulide Sup 1.07 Sup 0.07 <.005 <0.003 <.005 0.02 Sup <0.003 
Pravastatin <0.07 <0.05 <0.24 <0.05 <0.24 <0.05 <0.07 <0.16 <0.07 <0.16 
Propranolol Sup <0.02 Sup <0.02 Sup <0.02 Sup 0.26 Sup <0.02 
Salicylic acid <0.09 <0.11 <0.09 <0.11 <0.09 <0.11 <0.09 <0.11 <0.09 <0.11 
Trimethoprim <0.17 <0.07 <0.17 0.25 <0.17 0.32 <0.17 0.1 <0.17 <0.07 
BOD (mg/L) 300 4 330 2 350 5   270 2 
COD (mg/L) 545 34.1 712 28.6 927 30.6   562 38.8 
pH 7.75 7.52 7.8 7.43 7.71 7.23   7.6 7.52 
SS (mg/L) 401 17 247 11 407 13   253 9 
Flowrate (m3/d)  11991 9570 10216  12259 
Rainfall (mm) 1.3 0 0 0.4 7.8 
Temperature (0C) 17.8 18.3 16.2 13.6 9.7 
Sunshine (h) 4.8 8.8 5.0 0 3.6 
Table 3.6.1 Concentration of analytes (µg/L) detected in Swords WWTP samples (Inf = Influent; Eff = Effluent;  
Sup = Suppressed signal). BOD, COD, SS and flowrate data were obtained from the WWTP. Rainfall, temperature 
and sunshine data were obtained from the Met Éireann 
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 Jan 2008 Feb 2008 Mar 2008 April 2008 June 2008 
 Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff 
Bezafibrate <0.03 0.12 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 
Caffeine <0.28 <0.46 <0.28 <0.46 <0.28 <0.46 <0.28 <0.46 <0.28 <0.46 
Carbamazepine <0.03 0.59 0.15 0.30 <0.03 0.25 <0.03 0.60 1.52 <0.01 
Clotrimazole <0.03 0.12 <0.03 <0.01 <0.03 <0.01 <0.03 <0.01 <0.03 <0.01 
Diclofenac Sup <0.74 Sup <0.74 Sup 2.95 <0.86 <0.74 <0.86 <0.74 
Furosemide 0.45 0.44 <0.09 <0.11 <0.09 0.30 <0.09 0.85 <0.09 <0.11 
Mefenamic acid Sup <0.004 Sup <0.004 Sup <.004 Sup <.004 Sup <.004 
Metoprolol Sup <0.10 Sup <0.10 Sup 0.12 Sup <0.10 Sup <0.10 
Nimesulide <.002 <.001 <.002 <.001 <.002 <.001 <.002 <.001 0.25 <0.003 
Pravastatin <0.07 <0.05 <0.07 <0.05 1.85 <0.16 <0.07 <0.05 <0.07 <0.05 
Propranolol Sup <0.02 Sup <0.02 Sup <0.02 <.007 <0.02 <.007 <0.02 
Salicylic acid <0.03 Sup <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 
Trimethoprim <0.17 <0.02 Sup <0.02 15.7 0.85 <0.17 <0.02 Sup <0.02 
BOD (mg/L) 420 7 350 2 450 4   410  
COD (mg/L) 1220 51.4 1011 67.9 482 31 678 44.2 1087 99.6 
pH 7.91 7.49 7.64 7.24 7.64 7.58 7.76 7.59 7.48 7.93 
SS (mg/L) 475 10 331 22 446 17 308 13 489 27 
Flowrate (m3/d) 10945 9826 9666 11573 8714 
Rainfall (mm) 4.2 0 3.2 0.1 0 
Temperature (0C) 7.3 12.1 11.9 8.7 18.4 
Sunshine (h) 1.7 8.2 3.7 1.7 14.4 
Table 3.6.1 (continued) Concentration of analytes (µg/L) detected in Swords WWTP samples (Inf = Influent; Eff = 
Effluent; Sup = Suppressed signal). BOD, COD, SS and flowrate data were obtained from the WWTP. Rainfall, 
temperature and sunshine data were obtained from the Met Éireann. 
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 July 2007 August 2007 Sept 2007 Oct 2007 Nov 2007 Dec 2007 
 Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff 
Caffeine <0.28 3.05 3.79 <0.14 <0.93 <0.46 3.30 <0.14 <0.93 <0.46 <0.93 <0.14 
Carbamazepine <0.03 0.12 0.15 0.35 0.20 0.52 <0.03 <0.01 <0.03 0.50 0.28 0.32 
Clotrimazole <0.03 0.13 0.19 <0.01 <0.03 0.30 <0.03 <0.01 0.22 0.13 <0.03 0.11 
Diclofenac <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 
Furosemide <0.09 <0.37 <0.09 <0.37 <0.09 <0.11 <0.09 <0.37 <0.09 0.68 <0.09 <0.11 
Gemfibrozil 0.14 <0.01 <0.03 <0.03 <0.03 <0.01 <0.03 <0.01 <0.03 <0.01 <0.03 <0.03 
Mefenamic acid Sup <0.01 Sup 0.67 Sup <.004 Sup <.004 Sup <.004 Sup 1.73 
Metoprolol Sup <0.10 Sup <0.10 Sup <0.10 Sup 4.09 Sup <0.10 Sup <0.10 
Nimesulide 0.02 <.003 <.005 0.14 Sup <.003 <.005 <.003 Sup 0.35 <.005 0.13 
Pravastatin <0.07 <0.05 <0.07 <0.05 <0.07 <0.05 <0.07 <0.05 <0.07 <0.05 <0.24 <0.05 
Propranolol Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 
Salicylic acid 0.30 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.09 <0.12 
Trimethoprim <0.17 <0.02 <0.17 0.20 <0.17 <0.02 <0.17 <0.02 <0.57 0.57 0.87 0.41 
BOD (mg/L)   61 3.5   198 2.8 101 2.5 97 6.4 
COD (mg/L)   125 9 309 28 408 23 295 31 253 23 
pH   7.52 7.49 7.38 7.18 7.63 7.12 7.41 7.72 7.34 7.67 
SS (mg/L)   42 4 254 8 374 3 116 7 163 8 
Flowrate (m3/d) 11168 14711 9446 8179 9516 16714 
Rainfall (mm)  16.6 0.2 1.3 0.4 0  
Temperature (0C)  17 13.2 15.8 7.5 6.6  
Sunshine (h)  4.5 9.7 0.7 4.7 6.2 
Table 3.6.2 Concentration of analytes (µg/L) detected in Leixlip WWTP samples (Inf = Influent; Eff = Effluent; Sup = 
Suppressed signal). BOD, COD, SS and flowrate data were obtained from the WWTP. Rainfall, temperature and sunshine 
data were obtained from the Met Éireann 
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 Jan 2008 Feb 2008 Mar 2008 April 2008 May 2008 June 2008 
 Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff 
Caffeine <0.93 <0.14 <0.28 <0.14 <0.93 <0.14 <0.28 <0.14 <0.93 <0.14 <0.28 <0.14 
Carbamazepine <0.03 <0.01 <0.03 0.58 0.72 0.70 0.13 1.20 0.70 <0.01 0.77 1.20 
Clotrimazole <0.03 <0.01 <0.03 <0.01 <0.03 <0.01 <0.03 0.21 0.5 <0.01 <0.03 <0.01 
Diclofenac <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 0.73 <0.86 <0.74 
Furosemide <0.09 <0.11 <0.09 <0.11 <0.09 <0.11 1.00 <0.11 0.90 <0.37 1.70 <0.11 
Gemfibrozil <0.03 <0.01 <0.03 <0.01 <0.03 0.15 <0.03 0.12 <0.03 <0.01 <0.03 <0.01 
Mefenamic acid Sup <.004 Sup <.004 Sup <.004 Sup <.004 Sup 0.90 Sup <.004 
Metoprolol Sup <0.32 Sup <0.32 Sup <0.10 Sup <0.10 Sup <0.10 Sup <0.10 
Nimesulide <.002 <.001 <.002 <.001 <.002 <.003 <.002 <.001 <.002 <.001 <.002 <.001 
Pravastatin <0.07 <0.02 <0.07 <0.02 3.25 0.40 <0.07 <0.02 <0.07 <0.02 <0.07 <0.02 
Propranolol Sup <0.06 Sup <0.06 Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 
Salicylic acid <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 
Trimethoprim <0.17 0.46 <0.17 <0.02 <0.17 <0.02 <0.17 <0.02 0.25 <0.02 <0.17 <0.02 
BOD (mg/L) 114 2 200 2 102 5   206 3.8 299 7.7 
COD (mg/L) 398 23 414 23 343 26   650 67 447 57 
pH 7.40 7.09 7.38 7.10 7.47 7.26 7.38 7.15 7.28 7.24 7.43 7.21 
SS (mg/L) 182 4 104 4 102 2 278 9 452 14 190 13.5 
Flowrate (m3/d) 16920 13518 10518 10632 8812 8140 
Rainfall (mm) 1.8 1 0.7 1.5 0 0 
Temperature (0C) 8.6 9.4 4.7 11.1 19.9 23.3 
Sunshine (h) 0.1 5.1 3.4 6.6 9.4 9.7 
Table 3.6.2 (continued) Concentration of analytes (µg/L) detected in Leixlip WWTP samples (Inf = Influent; Eff = 
Effluent; Sup = Suppressed signal). BOD, COD, SS and flowrate data were obtained from the WWTP. Rainfall, 
temperature and sunshine data were obtained from the Met Éireann 
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 July 2007 Aug 2007 Sept 2007 Oct 2007 Nov 2007 Dec 2007 
 Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff 
Bezafibrate <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 <0.03 <0.15 
Caffeine <0.28 <0.14 <0.93 22.7 <0.93 <0.46 2.10 2.15 <0.28 <0.14 <0.28 <0.46 
Carbamazepine 0.45 0.60 0.23 0.49 0.45 0.70 <0.01 6.50 0.10 0.22 0.24 0.78 
Clotrimazole <0.01 0.50 0.65 8.65 0.35 0.28 <0.01 <.004 0.17 0.61 <0.01 0.10 
Diclofenac <0.86 0.50 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 
Furosemide 6.45 0.30 <0.09 <0.11 1.45 <0.11 <0.09 <0.37 <0.09 1.33 <0.09 <0.37 
Mefenamic acid Sup 9.1 Sup 0.29 Sup <.004 Sup <.004 Sup 0.30 Sup <.004 
Metoprolol Sup <0.32 <2.11 4.19 Sup <0.10 Sup <0.10 <2.11 4.34 Sup <0.10 
Nimesulide Sup 3.05 Sup 0.50 <.002 <0.003 0.88 <.001 <.002 <.001 <0.005 <.001 
Pravastatin 1.55 <0.05 <0.07 <0.05 <0.07 <0.05 <0.07 <0.05 <0.07 <0.05 <0.07 <0.05 
Propranolol Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 
Salicylic acid 12.8 <0.12 5.1 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 
Trimethoprim <0.17 0.62 <0.17 0.22 <0.17 <0.07 <0.17 <0.02 <0.17 <0.02 <0.17 <0.02 
BOD (mg/L) 191 5 186 15 323 16 259 7 227 10 232 13 
COD (mg/L) 409 59 426 46 843 71 566 50 615 49 530 56 
pH 7.5 7.6 7.6 7..8 7.6 7.7 7.6 7.6 7.6 7.5 7.5 7.6 
SS (mg/L) 240 18 176 18 396 26 316 19 276 19 241 19 
Flowrate (m3/d) 509245 391576 799043 349516 733549 368793 
Rainfall (mm) 5.3 0 0 1.3 8.9 0 
Temperature (0C) 15.4 17.9 19.0 15.8 8.8 7.3 
Sunshine (h) 4.9 2.4 8.4 0.7 0.1 6.9 
Table 3.6.3 Concentration of analytes (µg/L) detected in Ringsend WWTP samples (Inf = Influent; Eff = Effluent; Sup = 
Suppressed). BOD, COD, SS and flowrate data were obtained from the WWTP. Rainfall, temperature and sunshine data were 
obtained from the Met Éireann 
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 Jan 2008 Feb 2008 Mar 2008 April 2008 May 2008 June 2008 
 Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff Inf Eff 
Bezafibrate <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 <0.03 <0.05 
Caffeine <0.28 <0.14 <0.28 <0.14 <0.28 10.9 <0.28 <0.14 13.9 <0.14 0.50 <0.14 
Carbamazepine 0.30 0.45 <0.03 0.47 <0.03 0.25 0.51 <.004 0.20 <0.01 0.55 <0.01 
Clotrimazole <0.01 <0.01 <0.01 <0.01 <0.01 0.15 <0.03 <.004 <0.03 <0.01 <0.01 <.004 
Diclofenac <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 <0.86 <0.74 
Furosemide <0.09 <0.11 <0.09 <0.11 3.45 2.28 <0.09 <0.11 <0.31 0.35 <0.09 0.14 
Mefenamic acid Sup <.004 Sup <.004 Sup <.004 Sup <.004 Sup <.004 Sup <0.01 
Metoprolol Sup <0.10 Sup <0.10 Sup <0.10 Sup <0.10 Sup <0.10 Sup 2.0 
Nimesulide <.002 <.003 0.15 <.003 0.64 <.003 <.002 <.003 <.002 <.003 <.002 <.003 
Pravastatin <0.07 <0.05 <0.07 <0.05 <0.07 0.82 <0.07 <0.05 <0.07 <0.05 <0.07 <0.05 
Propranolol Sup <0.02 Sup 0.31 Sup <0.02 Sup <0.02 Sup <0.02 Sup <0.02 
Salicylic acid <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 <0.03 <0.12 
Trimethoprim 1.6 <0.02 <0.17 <0.02 <0.17 <0.07 <0.17 <0.02 0.10 <0.02 <0.17 <0.02 
BOD (mg/L) 70 15 278 6 183 39 220 13 565 15 248 8 
COD (mg/L) 159 53 543 66 352 130 438 62 1030 63 570 53 
pH 7.7 7.6 7.4 7.4 220 98 7.6 7.6 7.3 7.5 7.4 7.7 
SS (mg/L) 70 33 278 29 7.4 7.4 274 30 346 35 272 22 
Flowrate (m3/d) 837565 399936 492370 434566 352482 352043 
Rainfall (mm) 4.5 0 3.2 0.1 0 0 
Temperature (0C) 12.2 12.1 11.9 8.7 17.4 18.4 
Sunshine (h) 1.9 8.2 3.7 1.7 9.7 14.4 
Table 3.6.3 (continued) Concentration of analytes (µg/L) detected in Ringsend WWTP samples (Inf = Influent; Eff = Effluent; Sup = 
Suppressed signal). BOD, COD, SS and flowrate data were obtained from the WWTP. Rainfall, temperature and sunshine data 
were obtained from the Met Éireann 
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4.0 Discussion 
 
4.1 Matrix Effects 
 
One of the main characteristics of the method used in this study and of 
electrospray mass spectrometry in general is that it is subject to 
interference from organic and inorganic components in the matrix 
(Kasprzyk-Hrodern et al., 2008). This interference usually results in the 
suppression of analyte signals affecting the overall sensitivity of the 
method (Petrović et al., 2005). 
 
4.1.1 Addition Post Extraction 
 
The effects of matrix suppression/enhancement in influent and effluent 
matrices are presented in Table 3.3.1 (page 61). Four compounds 
(flurbiprofen, ibuprofen, metoprolol and propranolol) were suppressed by 
more than fifty percent in the presence of influent matrix components. 
Three compounds (salicylic acid, ibuprofen and salbutamol) were 
suppressed, also, by more than fifty percent in effluent matrix components. 
Ibuprofen exhibited the most intense suppression in both matrices at 
77.7% and 72.0% respectively. This may account for the poor linearity 
(0.8558) and reproducibility (34.7%) (Table 3.2.1 and 3.2.2, pages 58 and 
59) obtained during method validation. Ibuprofen was not detected in any 
sample during the twelve months which may also be due to the reduced 
analyte signal. The apparent high removal of salicylic acid observed in the 
three WWTPs may also be a result of increased suppression in effluent 
samples. To correct for any suppression or enhancement of analyte signal, 
internal standards or alternatively a method of standard additions can be 
used. In this study a wide range of compounds are being analysed and 
therefore a large number of internal standards would be required. The use 
of an inadequate number of internal standards for quantification may lead 
to an inaccurate quantification of signal suppression of each compound 
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and may result in under- or over-estimation of compound concentration. 
Therefore, standard addition was the chosen method for quantification. 
 
4.1.2 Post column infusion 
 
An additional study to illustrate the effects of signal suppression was 
undertaken for four compounds and the results are presented in Figures 
3.3.1. – 3.3.4 (pages 63 and 64). Signal suppression of nimesulide was 
quantified at 18.5% (influent) and <5% (effluent) in the addition post 
extraction experiment (Table 3.3.1). However, post column infusion 
showed almost complete suppression of the analyte signal at its retention 
time of 22 minutes. Suppression of the signal in the presence of the 
effluent extract confirmed the <5% suppression observed in the addition 
post extraction experiment. Mefenamic acid, also monitored in negative 
mode ionisation, showed extensive signal suppression in the presence of 
influent matrix components. The suppressive effect was less in the effluent 
sample. This is contradictory to what was observed in the addition post 
extraction study where no suppressive effect was determined in influent 
samples and 25.8% suppression in the presence of effluent matrix 
components. The complete suppression of signal in influent samples may 
account for the detection of mefenamic acid in effluent samples despite it 
being undetected in corresponding influent samples.  
Carbamazepine and trimethoprim were the two analytes monitored in 
positive mode ionisation which were selected for post column infusion 
studies. The results for carbamazepine show signal suppression in both 
influent and effluent samples (Figure 3.3.3). While the level of suppression 
was more pronounced than that observed in the post extraction addition 
study complete suppression of the analyte signal did not occur. The 
analyte signal suppression for trimethoprim was also greater in the post 
column infusion experiment than in the post extraction addition study. At 
the retention time of approximately two minutes there is significant 
suppression of both influent and effluent signals. The level of suppression 
caused by the influent matrix was greater than that caused by the effluent 
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matrix which is consistent with what was seen with the compounds 
analysed in negative mode. Variation in signal suppression observed for 
the four analytes investigated is due to the variation in matrix components 
between samples. 
Overall, the effect of matrix suppression is more pronounced in negative 
mode ionisation than positive mode ionisation. This has been observed in 
a previous study on the effect of environmental sample matrix components 
on electrospray ionisation (Benijts et al., 2004). Also, the suppressive 
effect is reduced from influent to effluent samples. This decrease is due to 
the reduction in organic and inorganic loading. Competition between the 
analytes and matrix components for access to the droplets surface and 
gas phase emission is one possible cause for matrix suppression in ESI 
(Benijts et al., 2004). Matrix effects were seen to be compound-dependent 
and previous studies on the suppressive effects of plasma have shown a 
decrease in matrix suppression with increased polarity of the compound 
(Bonfiglio et al., 1999). In this study, matrix suppression was seen to be 
compound-dependent but correlation between compound polarity and 
matrix suppression was not as clear. Carbamazepine is more polar than 
nimesulide and mefenamic acid. However the matrix effects observed for 
carbamazepine are lower. Of the two compounds analysed in positive 
mode ionisation trimethoprim, the more polar compound is suppressed to 
a greater degree. This is in line with what was reported by Bonfiglio et al., 
1999. In the absence of a database of mass spectra for substances, two 
further investigations were completed in an attempt to elucidate the 
compounds which may be responsible for the increased matrix 
suppression. Firstly, the effects of surfactants in influent and effluent 
samples was investigated and secondly, the presence of metals was 
established (Section 4.2).   
 
4.1.3 Standard additions 
 
A method of standard additions was used in this analysis for quantification 
to ensure the accurate reporting of concentrations present in wastewater 
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streams. The linear plots used for quantification of analytes in November 
2007 are included in Figures 3.3.5 – 3.3.8, 3.3.10 – 3.3.14, 3.3.19 – 3.3.23 
(pages 67-70, 72-76, 81-85) for illustration. Good linearity of standard 
addition was required for quantification in this analysis. Only plots with a 
correlation coefficient of ~0.9 or above were used for quantification during 
the twelve months sampling. Using this method the emergence of 
compounds during treatment could be investigated. For example, 
nimesulide was detected in the effluent sample from Leixlip in November 
2007 while the concentration present in the influent stream was below 
detection limits. This was considered a true result as an analyte response 
was observed for the standard additions in the influent sample (Figure 
3.3.7, page 69). In the same month, trimethoprim was also detected in the 
effluent sample but was absent from the influent. When the standard 
additions for trimethoprim in the influent matrix were analysed, no signal 
for trimethoprim was detected (Figure 3.3.9, page 71). This result indicates 
that there may in fact have been trimethoprim in the influent stream but 
that it was masked by the suppressive effects of matrix components. This 
result is in line with what was observed in the addition post extraction and 
post column infusion investigations. The same observation was made for 
furosemide in the November sample at Leixlip. Similarly, some compounds 
detected in the effluent and not in influent samples from Swords treatment 
facility had complete signal suppression of standard additions in the 
influent (furosemide, trimethoprim, mefenamic acid and propranolol). This 
suppressive effect was also observed for furosemide and mefenamic acid 
in influent streams at Ringsend. 
The significant matrix suppression identified in the analysis of influent 
samples in this study indicates that the extent of pharmaceutical 
contamination in influent samples cannot be determined for specific 
analytes. Flurbiprofen, mefenamic acid, diclofenac, clofibric acid, 
sulfamethoxazole and ibuprofen analyte signals were completely 
suppressed in influent samples from the three treatment plants. Complete 
signal suppression was also observed for indomethcin and salbutamol in 
influent samples from the Swords treatment plant. It also calls into question 
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the hypothesis put forward by numerous authors that metabolites are 
deconjugated, during wastewater treatment, to yield the parent compound 
as an explanation of increasing effluent concentrations (Ternes, 1998; 
Heberer et al., 2002; Miao et al., 2002; Lishman et al., 2006). 
 
4.2 Metal and Surfactant Analysis 
 
The metal analysis completed by TMS Environmental Ltd. showed that 
only trace quantities of metal were present in influent and effluent streams. 
Also, where metals were detected there was no significant variation 
between influent and effluent samples. This indicates that suppression of 
analyte signal during analysis is not associated with metal related 
interferences. 
The effect of LAS on the signal suppression of four compounds 
(nimesulide, mefenamic acid, carbamazepine and trimethoprim) was 
investigated. LAS products contain a mixture of homologues with alkyl 
chain lengths from C10 to C13. However, for the purpose of this 
investigation, monitoring of the individual species was not included 
because an overall picture of the presence and suppressive effect of the 
surfactant on analysed standards was required. Signal suppression of 
>90% was observed for three of the selected analytes (trimethoprim, 
nimesulide and mefenamic acid), while a signal increase of 7.92% was 
observed for carbamazepine. Alteration of peak shape and retention of 
compounds was also effected by the presence of the surfactant. The 
retention time of nimesulide was reduced by 2.5 minutes and the retention 
of mefenamic acid was also reduced by up to 0.8 minutes (Figure 3.5.1, 
page 90). No effect on retention of carbamazepine was observed. 
Retention time may have been reduced due to interactions with the 
surfactants allowing for accelerated transport of compounds through the 
column. Suppressive effects may be due to the surfactant binding with the 
compounds masking their presence or neutralising the charge preventing 
ionisation. 
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The presence of the surfactant did not cause complete suppression of 
the analyte signal for mefenamic acid. Therefore, the presence of the 
surfactant LAS in influent samples would be unlikely to have caused the 
low detection of mefenamic acid in influent samples. Similarly, the 
carbamazepine analyte signal was not completely suppressed and the 
presence of LAS in influent samples would not have prevented the 
detection of carbamazepine. The response for both nimesulide and 
trimethoprim was significantly altered. The analyte signal for nimesulide 
was completely suppressed similar to that observed in the post column 
infusion investigation for nimesulide (Figure 3.3.1, page 63). The peak 
shape of the trimethoprim standard in the presence of LAS was completely 
altered so that quantification would not be possible.  
4.3 Monthly Sampling 
 
The results of the monthly sampling programme are presented in Section 
3.6. Overall, low concentrations (µg/L) of fifteen compounds were detected 
in wastewater streams. The individual concentrations present in effluent 
streams are mostly below that which may impart any toxic effect to aquatic 
organisms (Table 1.5.1). Nevertheless, there is one cause for possible 
concern, the concentration of mefenamic acid in effluent streams. Using 
predicted no effect concentrations and the measured effluent 
concentration the risk quotients of the effluent streams are >1, indicating a 
potential ecotoxicological risk with sewage effluent. However, when a 
commonly employed dilution factor of 10 is taken into account the risk 
quotient is reduced to below 1. 
Removal of pharmaceuticals from a wastewater stream during treatment 
is affected by numerous factors including: the physio-chemical nature of 
the compound, the composition of the sewage as well as weather 
conditions and operational parameters of the treatment process. 
Consequently, to determine the impact of such parameters, influent and 
effluent concentrations were plotted against pKa (acid dissociation 
constant) and log P (partition coefficient) values and operational values 
(flowrate, biological oxygen demand (BOD), chemical oxygen demand 
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(COD), pH and suspended solids (Appendices B, C and D). No 
relationships were observed. Weather conditions such as temperature and 
rainfall have been shown to affect the concentration of pharmaceuticals in 
influent and effluent samples. These parameters were analysed however 
no relationships were determined. The effects of temperature, rainfall and 
hours of sunshine have also been shown to correlate with removal rates. 
However, as a significant number of the analytes under investigation was 
detected only in effluent samples and not in corresponding influent 
samples, removal efficiencies could not be determined for the majority of 
compounds. While these apparent increases in concentration may be due 
to the emergence of the parent compound following deconjugation of 
metabolites during wastewater treatment (Ternes, 1998; Lishman et al., 
2006), it is more likely to be as a result of suppressed analyte signal during 
analysis of influent samples as discussed in Section 4.1.  
As the analyte signal for carbamazepine was not completely suppressed 
in either influent or effluent matrices and good linearity was attained for 
standard additions in influent and effluent samples, removal efficiencies for 
this analyte could be analysed. In general no removal of carbamazepine 
was observed in the three treatment plants with the concentration 
apparently increasing during treatment. For example, Table 4.3.1 
highlights the increase (+) or decrease (-) in concentration observed in the 
Leixlip plant over the twelve months.  
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 Influent Effluent Change 
July 07 <LOD 0.12 + 0.12 
August 07 0.15 0.35 + 0.20 
September 07 0.20 0.52 + 0.32 
October 07 <LOD <LOQ 0 
November 07 <LOD 0.50 +0.50 
December 07 0.28 0.32 +0.04 
January 08 <LOQ <LOQ 0 
February 08  <LOQ 0.58 +0.58 
March 08 0.72 0.70 -0.02 
April 08 0.13 1.20 +1.07 
May 08 0.70 <LOQ -0.70 
June 08  0.77 1.20 +0.43 
Table 4.3.1 Change in carbamazepine concentration (µg/L) in influent 
and effluent samples at the Leixlip plant. 
 
This behaviour was also observed in previous studies (Clara et al., 2004).  
However, with an increase in temperature and daylight hours and a 
reduction in flow to the plants from April to June, removal of 
carbamazepine from effluent streams at the Ringsend plant was greater 
than 99% (Figure 4.3.1). In samples from the Swords plant in June over 
99% removal was also observed. It can be assumed that the removal of 
carbamazepine during wastewater treatment is a result of degradation, as 
sorption to sludge would not be expected due its low Kow (octanol-water 
partitioning coefficient) of 2.25. Removal, due to adsorption alone, 
determined in other investigation has been low at < 10% (Clara et al., 
2004; Ternes et al., 2005). Microbial activity is temperature dependent and 
therefore higher removal rates would be expected during the summer 
(Castiglioni et al., 2006). The complete removal of carbamazepine in April, 
May and June 2008 seen at the Ringsend plant may also be as a result of 
photolysis. UV tertiary treatment is used to treat effluent from the plant 
during the bathing season. Direct photolysis of carbamazepine using an 
immersed medium-pressure mercury lamp in ideal conditions (Milli-Q 
water) has shown that carbamazepine is degraded to six intermediates 
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(Chiron et al., 2006). 100% removal efficiencies were observed during the 
bathing season, while removal of up to 20% was determined at other times 
during the year (Ringsend data Figure 4.3.1).  
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Figure 4.3.1 Influent and effluent concentrations of carbamazepine (July 
2007 – June 2008). 
 
Statistical analysis of calculated influent and effluent concentrations was 
completed. A method of standard additions was used to determine the 
concentration of each analyte in both influent and effluent samples. This method 
allowed for a calibration graph and measurement of concentrations relative to 
the effects of the matrix to be obtained. As a number of concentrations are used 
to determine the concentration the standard deviation of the extrapolated 
concentration is calculated using equation (1). 
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The 95% confidence limits of the extrapolated concentrations are equal to the 
standard deviation of the extrapolated concentration multiplied by the 95% 
confidence t value.  
 
The calculated confidence limits indicate that the concentrations obtained for 
each of the analytes are subject to wide variation. This is due in part to the low 
number of points on each of the calibration curves. Ideally six points would be 
used for a standard addition experiment as the greater the value of n (number 
of data points) the more precise the estimated concentration (Miller and Miller, 
1993). However, due to the limited sample volume (2 litres) available from each 
of the sample locations monthly, a maximum of 4 samples could be analysed in 
this work. That is the raw sample with no addition of a standard and three 
samples with a standard addition. This reduced value of n means that the 
degrees of freedom (n-2) used to determine the t value in the calculation is 2. 
The concentrations obtained in this work are however are deemed to be valid 
as the calibration curves yielded high regression coefficients. 
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Ringsend 
Nov 07 
Swords 
Nov 07 
Leixlip 
Nov 07 
Ringsend 
April 08 
Ringsend 
April 08 
Leixlip 
April 08 
 Conc CL Conc CL Conc CL Conc CL Conc CL Conc CL 
Carbamazepine (Inf) 0.10 0.56 - - 0.22 0.60 0.51 9.78 0.60 5.81 1.30 2.04 
Carbamazepine (Eff) 0.22 2.17 0.25 1.40 0.50 1.40 - - - - 1.20 2.57 
Clotrimazole (Inf) 0.17 3.22 0.90 1.53 0.05 1.13 - - - - - - 
Clotrimazole (Eff) 0.61 0.73 1.20 1.48 0.13 1.30 - - - - 0.21 0.70 
Nimesulide (Inf) 0.88 7.04 - - - - 0.10 1.30 - - - - 
Nimesulide (Eff) - - 0.20 0.87 0.35 2.50 - - - - - - 
Furosemide (Inf) - - - - - - - - 0.85 8.60 0.45 0.72 
Furosemide (Eff) 1.33 6.73 0.50 9.82 0.68 1.14 - - - - - - 
Trimethoprim (Eff) - - 0.12 0.73 0.57 8.98 - - - - - - 
Metoprolol (Inf) 1.70 2.10 - - - - - - - - - - 
Mefenamic Acid (Eff) 0.30 4.77 - - - - - - - - - - 
Propranolol (Eff) 0.26 1.19 - - - -- - - - - - - 
Diclofenac (Eff) 0.24 0.15 - - - - - - - - - - 
Gemfibrozil (Eff) 0.12 0.15 - - - - - - - - - - 
Table 4.3.2 Confidence limits for extrapolated concentrations from November 2007 and April 2008 for the three WWTPs. 
Conc = Concentration (µg/L); CL = Confidence Limit (µg/L). 
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4.4 Seasonal Trends 
 
As influent concentration data sets are incomplete due to matrix ion 
suppression effects, data from effluent streams were examined for 
seasonal trends. The total effluent concentrations for each plant, in µmol, 
were plotted against flowrates and temperature. The plots are presented in 
Figures 4.4.1, 4.4.2 and 4.4.3. Lower effluent concentrations were 
observed with increased flowrate and reduced temperatures (Figure 4.4.1 
– see range from November 2007 – March 2008). This may be due to a 
higher dilution factor because of increased rainfall and also reduced 
biodegradation at lower temperatures. Reduced flowrates and higher 
temperatures also resulted in low effluent concentrations in August and 
September 2007 and April - June 2008 in Figure 4.4.1, which would be 
consistent with an expected increase in biodegradation at increased 
temperatures. Similar trends are seen in the Ringsend and Swords plants 
(Figures 4.4.2 and 4.4.3, page 112 and 113). The trends observed here 
are generally in line with those seen in previous investigations (Castiglioni 
et al., 2006; Vieno et al., 2005). The removal of eight compounds was 
reduced during winter months. For example, sulfamethoxazole had 
removal rates of 71% in summer which reduced to 17% in winter 
(Castiglioni et al., 2006). While the total removal levels increased from 
61% in March to 88% in August in the Aura WWTP (Vieno et al., 2005). 
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Figure 4.4.1 Cumulative concentration of pharmaceuticals in effluent at 
Leixlip WWTP and daily temperature and flowrates (July 2007 – June 
2008)  
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Figure 4.4.2 Cumulative concentration of pharmaceuticals in effluent at 
Ringsend WWTP and daily temperature and flowrates (July 2007 – June 2008)  
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Figure 4.4.3 Cumulative concentration of pharmaceuticals in effluent at Swords 
WWTP and daily temperature and flowrates (August 2007 – June 2008)  
 
 
4.5 Analyte occurrence 
 
The occurrence of analytes in influent and effluent streams from the three 
wastewater treatment facilities will be discussed here by therapeutic class 
and toxicity will be discussed where data are available. 
 
Analgesics/Anti-inflammatories 
 
Of the twenty compounds selected for this investigation six (diclofenac, 
flurbiprofen, ibuprofen, indomethcin, mefenamic acid and nimesulide) are 
anti-inflammatories. Salicylic acid, a metabolite of the analgesic 
acetylsalicylic acid, will also be included under this heading. 
Concentrations of flurbiprofen, ibuprofen and indomethcin were below 
limits of detection in all influent and effluent samples during this study. 
Significant analyte signal suppression was observed for ibuprofen (>70%) 
in the addition post extraction study (Table 3.3.1). This indicates that the 
effects of signal suppression may account for the absence of ibuprofen 
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from influent and effluent streams. Standard additions in influent and 
effluent samples confirmed that the absence of ibuprofen was due to signal 
suppression, as no signal was identified for ibuprofen in either matrix. 
Significant suppression of flurbiprofen and indomethcin was also observed 
(Table 3.3.1) with suppression values of up to 60.5% and 44.2% exhibited 
respectively. Again suppression of the analyte signal affected the analysis 
of these compounds with standard additions confirming suppression of the 
signal with complete suppression being observed in influent matrices.  
Salicylic acid was detected only in influent samples over the sampling 
period. Removal of salicylic acid is expected as it is readily biodegradable 
and has a high removal rate during wastewater treatment (Daughton and 
Ternes, 1999). Residues of salicylic acid in environmental samples are not 
necessarily from acetylsalicylic acid. Other sources include its use in food 
preservation or in acne medications (Heberer, 2002). Theoretical toxicity 
data obtained using ECOSAR indicate that EC50 values for salicylic acid 
are in mg/L quantities (Sanderson et al., 2003). ECOSAR is an ecological 
structure activity relationships model that estimates the toxicity of 
chemicals to aquatic organisms based on similarities in molecular structure 
to chemicals for which toxicity data are available. The absence of salicylic 
acid in effluent streams indicates that there is no threat to the environment.  
Diclofenac was present in a limited number of effluent samples from the 
three plants during the sampling period (July 2007 – June 2008). In 
corresponding influent samples the concentration of diclofenac was below 
detection limits. Results from initial sample analysis by LC-MS also 
showed an increase in analyte concentration during wastewater treatment 
(Appendix A). Poor removal rates were observed in previous studies 
(Buser et al., 1998, Stumpf et al., 1999, Zwiener et al., 2000). Suggested 
reasons for this emergence pattern include deconjugation of conjugated 
metabolites over the treatment process as the primary metabolites of 
diclofenac are glucuronides and sulphate conjugates which may be 
cleaved during wastewater treatment and release the parent compound. 
On the other hand ion suppression in influent matrices may result in a 
reduction in intensity of the signal and mask the presence of the 
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compound. Ion suppression was quantified at 23.7% in influent samples 
(Table 3.3.1). Complete suppression of standard additions was observed 
in influent samples. Concentrations observed in effluent samples (0.24µg/L 
– 2.95µg/L) in this study are in line with those previously reported (Table 
1.2.1).  
Mefenamic acid was detected in approximately 35% of effluent samples 
while corresponding influent samples did not contain mefenamic acid at a 
quantifiable level. Similar trends of occurrence in effluent samples were 
observed in early investigations with LC-MS analysis (Appendix A). This is 
most likely due to the suppression of compound signal in influent samples 
(Figure 3.3.2). The results obtained in the post column infusion 
investigation and subsequent standard additions show that mefenamic 
acid could not be determined in influent samples due to the complete 
suppression of analyte signal caused by the influent matrix. As a result 
removal rates for mefenamic acid could not be determined. However, it is 
clear from the results obtained that the removal of mefenamic acid from 
wastewater streams is incomplete in investigated plants. Ecotoxicity data 
are not available for mefenamic acid, however a predicted no effect 
concentration (PNEC) of 0.428µg/L was established previously using 
ECOSAR (Jones et al., 2002). Here effluent concentrations of mefenamic 
acid, at both the Leixlip and Swords plants, exceeded this value. The 
maximum risk quotient, MEC/PNEC (measured environmental 
concentration (effluent concentration)/predicted no effect concentration), 
for mefenamic acid in effluent streams at the three plants were 0.70 
(Ringsend), 4.04 (Leixlip) and 1.33 (Swords). This indicates a potential 
ecotoxicological risk associated with the concentrations being released to 
the environment at two plants, Leixlip and Swords. If a commonly used 
dilution factor of 10 is employed (Halling-Sørensen et al., 2000; Jones et 
al., 2002) the risk quotient is significantly reduced to below 1 which implies 
that there may be no risk associated with this analyte. Experimental toxicity 
data for mefenamic acid are currently unavailable and would be required to 
accurately determine no effect concentrations and also to ascertain 
specific toxicological effects.  
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Nimesulide was suspended from the Irish market in May 2007. Following 
a review of the safety of nimesulide by the European Medicines Evaluation 
Agency licences for systemic formulations of nimesulide were revoked in 
December 2007. However, 3% gel formulations are still licensed for use 
(Nimesulide, IMB). Monitoring of influent and effluent streams for this 
compound showed a decline in the concentration present at the Ringsend 
site from July to September 2007 (Figure 4.5.1). This decline is in keeping 
with the decrease in usage of the compound. Levels at the other two 
WWTPs were less than 30% of the concentration recorded at Ringsend in 
July. Residual levels present in wastewater streams are likely due to the 
usage of gel formulations still available on the market. 
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Figure 4.5.1 Decline in effluent concentrations from the three investigated 
wastewater treatment plants 
 
Anti-convulsant 
Carbamazepine was detected every month in the three wastewater 
treatment plants. It is an anti-convulsant used primarily in the treatment of 
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epilepsy as well as bipolar depression and trigeminal neuralgia. 
Concentrations ranging from 0.10-1.52 µg/L were detected in the three 
WWTPs with the exception of the Ringsend effluent sample in October 
2007 which contained 6.5 µg/L of carbamazepine. These concentrations 
are in line with other studies which found levels of 3.7 µg/L (Ternes, 1998) 
and 0.3-1.85 µg/L (Clara et al., 2004) in sewage influent and effluent 
samples. Here an increase in effluent concentration compared to influent 
concentration was observed at the three WWTPs in more than 90% of 
samples (Table 3.6.1, 3.6.2 and 3.6.3). On average 72% of ingested 
carbamazepine is eliminated from the body in the urine of which 2-3% is in 
the form of the parent compound. The remainder is excreted as an array of 
metabolites including glucuronide conjugates (Maggs et al., 1997; Ternes, 
1998). Deconjugation may occur during wastewater treatment, which 
would account for the increase in the final effluent concentration. As 
complete suppression of carbamazepine did not occur and the compound 
could be quantified in influent samples matrix suppression is not 
responsible for this increase in concentration during treatment. 
Carbamazepine would be expected to have low sorption potential with a 
log Kow of 2.25 (Scheytt et al., 2005a; Jones-Lepp and Stevens, 2007). 
Minimal or no biodegradation or adsorption of carbamazepine during 
wastewater treatment was reported previously. Removal rates from 
conventional activated sludge treatment and during infiltration of treated 
wastewater to groundwater ranged from 0 - 8% (Castiglioni et al., 2006; 
Clara et al., 2004; Heberer, 2002; Ternes, 1998). Consequently 
carbamazepine has been suggested as a good indicator of wastewater 
contamination in the aquatic environment (Clara et al., 2004). Preliminary 
analysis on river water approximelety 1.5km downstream of the Leixlip 
plant discharge point identified carbamazepine. A concentration of 
0.22µg/L was determined using standard additions with an R2 value of 
0.98. This also indicates that carbamazepine may be a good marker of 
effluent contamination. Recent studies on the toxicity of carbamazepine to 
the cnidarian, Hydra attenuate, show carbamazepine has an EC50 of 
3.76mg/L (Quinn et al., 2008), which is below the effluent concentration 
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found in this work. This suggests that there is no ecotoxicological risk 
associated with the quantities of carbamazepine being released from the 
three plants.   
 
Lipid Modifying Agents 
Bezafibrate, a fibrate drug, is used for the treatment of hyperlipidemia. 
Bezafibrate was not detected in the majority of samples analysed in this 
study. Only two samples from Swords, one influent and one effluent, and 
one effluent sample from Ringsend contained bezafibrate. There was no 
occurrence of bezafibrate in Leixlip. The addition post extraction 
investigation results indicated that the analysis of bezafibrate was not 
affected by matrix suppression with <5 % recorded in both influent and 
effluent (Table 3.2.2). Due to the infrequent occurrence of bezafibrate in 
the three samples no judgment on the performance of the wastewater 
treatment process could be made.  
Clofibric acid is a metabolite of clofibrate and is commonly detected in 
environmental samples in European countries (Table 1.2.1). Clofibric acid 
was not detected in any sample analysed during this study.  Detection of 
clofibric acid would not be expected in this study as clofibrate is no longer 
available on prescription in Ireland. Clofibric acid was included in this study 
due to its ubiquitous nature in other European countries, and also to show 
that the occurrence of residual pharmaceuticals and metabolites can be 
used to indicate the use of specific compounds. The matrix suppression 
quantified in the addition post extraction experiment was less than 30%. 
Standard additions showed that complete suppression of the analyte 
occurred in influent samples from the three WWTPs while standard 
additions in effluent samples gave good correlations (>0.9). 
Propranolol and metoprolol are two β-blockers used primarily for the 
treatment of hypertension. In 100% of the occurrences of metoprolol and 
propranolol at the Leixlip and Ringsend plant the concentration apparently 
increased during treatment. In the August sample from Swords treatment 
plant metoprolol was detected in the influent sample while the 
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concentration was below detection limits in the corresponding effluent 
sample. Propranolol is metabolized in the liver and one of the metabolites 
is a glucuronide of the parent compound (Mehvar and Brocks, 2001). 
Deconjugation to the parent compound during treatment may account for 
the increase in concentration. As significant suppression was observed for 
propranolol and metoprolol, 88.7% and 52.8% respectively, masking of the 
compound in influent samples is the more likely reason. Standard additions 
of propranolol in the influent sample from Swords in November 2007 show 
the absence of signal for the compound at ~11 minutes, and confirmed 
that suppression is the more likely reason for an absence of propranolol in 
the influent.  
Gemfibrozil is a member of the fibrate group of drugs and is used to 
lower lipid levels in the body. Gemfibrozil was detected only in samples 
taken from the plant at Leixlip. Concentrations ranged from LOQ–0.15 µg/L 
in effluent samples. Again gemfibrozil was most frequently detected in 
effluent samples. Suppression of the analyte signal may account for the 
apparent absence of gemfibrozil in influent streams as 45.6% suppression 
was determined in influent streams. The peak areas for standard additions 
in influent samples were ~70% less than the equivalent in effluent 
samples. 
Pravastatin is one of the naturally occurring statins. It is a lipid-lowering 
agent used in the treatment of cardiovascular disease. Literature on the 
occurrence and removal of pravastatin in the environment is limited. 
Reported concentrations of pravastatin in influent and effluent samples 
from a Canadian WWTP were 117ng/L and 59ng/L respectively, showing a 
removal of 50% (Miao and Metcalfe, 2003). In this study pravastatin was 
detected in a limited number (eight) of samples. Where influent and 
effluent concentrations were quantified removal rates ranging from 88 – 
100% were observed (Table 3.6.1, 3.6.2 and 3.6.3). While pravastatin was 
quantified in influent and effluent samples complete suppression of the 
analyte signal was occurred in other samples. This highlights the high 
degree of sample to sample variability in matrix suppression.  
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Anti-fungals/Antibiotics 
Clotrimazole, an anti-fungal agent, was detected in influent and effluent 
samples from the three WWTP at concentrations ranging from LOQ-0.65 
and LOQ-1.2µg/L with the exception of 8.65µg/L in August 2007 at 
Ringsend. Clotrimazole has a log Kow of 4.1 and so would be expected to 
exhibit medium to high sorption potential (OSPAR Commission, 2005; 
Jones-Lepp and Stevens, 2007). In this study clotrimazole concentrations 
increased in effluent over corresponding influent in the majority of cases 
(~70%). As linear standard additions were achieved for the quantitation of 
clotrimazole in both sample types, it is evident that the increase in 
concentration is not due to matrix effects. Limited occurrence or toxicity 
data are available on the level of clotrimazole in the environment. 
Clotrimazole has been quantified in a WWTP effluent and the river Tyne 
with median concentrations of 17ng/L and 21ng/L respectively. Despite the 
lack of information available clotrimazole is included on the list of 
chemicals for priority action (OSPAR commission, 2007).  
The occurrence of two antibiotics (trimethoprim and sulfamethoxazole) 
was also investigated. These two compounds are commonly prescribed in 
combination. Sulfamethoxazole was not detected in any samples. The 
absence of sulfamethoxazole is due to complete suppression of the 
analyte signal in influent matrices from the three plants as highlighted by 
the standard additions. Trimethoprim was present in either influent or 
effluent or both samples in more than forty percent of samples. In some 
samples trimethoprim was detected in effluent samples and absent from 
corresponding influent samples. However, when quantifiable in both 
streams 95-100% removal was observed in samples from Swords in March 
2008 and the Ringsend and Leixlip plants in May 2008. Maximum 
concentrations of up to 0.85µg/L were observed in effluent streams. The 
presence of antibiotics in wastewater treatment plants and effluent streams 
is of great concern to public health due to the potential development of 
antibiotic resistance among strains of bacteria. The toxicity of trimethoprim 
to aquatic organisms has been investigated. Chronic exposure studies 
have established that trimethoprim has an effective concentration (EC10) of 
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1.0mg/L on the duckweed, Lemna gibba (Crane et al., 2006). In a 48h test 
on Daphnia magna trimethoprim had an EC50 of 123mg/L. Calculated 
PEC/PNEC ratios were also <1 (Halling-Sørensen et al., 2000). Thus 
trimethoprim is thought to pose minimal threat to aquatic species at the 
current usage level (Crane et al., 2006). While the concentrations 
observed in this study and in other studies (Tables 1.2.1, 3.6.1, 3.6.2 and 
3.6.3) are below determined effective concentrations there is still the 
potential development of antibiotic resistance.  
 
Others 
Caffeine is considered as a central nervous stimulant. In general it was 
readily removed from the WWTPs. As the log Kow of caffeine is -0.1, 
sorption to sludge is unlikely so the main mechanism of removal is 
assumed to be biodegradation (Jones-Lepp and Stevens, 2007; Weigel et 
al., 2004). The occurrence of caffeine in a variety of environmental 
matrices has been widely reported (Halling-Sørensen et al., 1998; Ternes 
et al., 2001; Heberer, 2002; Koplin et al., 2002; Weigel et al., 2002; Koplin 
et al., 2004; Weigel et al., 2004; Bendez et al., 2005). Concentrations 
determined in influent samples in this study are consistent with ng-µg/L 
concentrations previously reported. 
Furosemide is a loop diuretic. Maximum concentrations observed in 
effluent streams in this study were 2.6µg/L. The lowest reported EC50 were 
2.4 mg/L in the crustacean, Ceriodaphnia dubia and 2.5 mg/L in the 
zooplankton Brachionus calyciflorus (Isidori et al., 2006). Accordingly the 
concentrations found in the present effluent samples would not be 
expected to impart any toxic effect in the environment.  
Salbutamol is a β2 agonist used for the treatment of respiratory diseases 
such as asthma. Salbutamol was included in this study because it is one of 
the top ten prescribed compounds in Ireland. However it was not detected 
in the analysed wastewater samples. This may be because it is 
predominantly prescribed as an inhaler and therefore does not enter 
wastewater streams. The addition post extraction experiment indicated that 
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there was minimal suppression of the analyte signal in influent samples 
and greater suppression (77%) in effluent samples. The use of standard 
additions showed that suppression in influent samples was significant with 
no analyte signal observed in influent samples. Therefore, the absence of 
salbutamol from analysed samples may also be due to suppression of the 
signal. 
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5.0 Artificial Neural Networks 
 
The fate of pharmaceuticals in wastewater treatment processes is complex 
and not well known or understood. Relationships between effluent 
concentration and weather data including rainfall, hours of sunshine and 
temperature and plant operation data (BOD, COD, flow, pH and 
suspended solids) were investigated however no trends were observed. As 
a result, the application of an artificial intelligence method was attempted. 
Artificial neural networks (ANN) were examined to predict effluent 
concentrations from WWTPs as a function of various weather conditions 
and plant input parameters. ANNs have been successfully used for 
prediction and forecasting in a number of fields including water resources, 
power generation and medicine. The design of a neural network is similar 
to that of the network of neurons in the brain and central nervous system. 
The networks are arranged in a series of layers including an input layer, 
one or more hidden layers and an output layer (Figure 5.0.1). The data 
from each node in the input layer pass to the hidden layer and are 
multiplied by the connection weight. In each hidden layer node the 
weighted values are summed and a threshold value is added. The output 
of each node is then determined by a non-linear transfer function of the 
summed input value. These outputs are the inputs of the next layer in the 
network. The final output is then compared to the known actual output for 
the training set and the connection weights applied are adjusted to reduce 
the prediction error (Maier and Dandy, 1998; Gurney, 2003). This form of 
ANN is called multilayer perceptron.  
Data collected from the three wastewater treatment plants were used to 
construct a model to predict effluent concentrations using neural networks. 
Carbamazepine occurred most frequently in the treatment plants and 
therefore the model was constructed to predict carbamazepine 
concentrations (Table 5.0.1). The network structure was optimised using a 
trial and error approach. The data were divided into three sections for 
training, validation and testing. Each network was trained using back 
propagation until the root mean squared error (RMS) value of the 
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validation data set began to increase. Back propagation is a useful and 
frequently used method for environmental models (Maier and Dandy, 
1998). Validation data were used to prevent overtraining of the network by 
performing cross validation. Networks consisting of one and two hidden 
layers were analysed and the results are shown in Figures 5.0.2 and 5.0.3. 
One hidden layer with 5 neurons was found to be the best configuration as 
it produces the lowest RMS error and was therefore chosen for further 
analysis.  
 
 
Figure 5.0.1 9-5-1 Network construction 
 
 
Input Layer 
Hidden Layer 
Output Layer 
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Plant CarbIn Rain Temp Daylight Flow COD BOD SS CarbOut 
1 0.45 5.3 15.4 4.9 509245 409 191 240 0.6 
1 0.23 0 17.9 2.4 391576 426 186 176 0.49 
1 0.45 0 19 8.4 799043 843 323 396 0.7 
1 0.1 8.9 8.8 0.1 733549 615 227 276 0.22 
1 0.24 0 7.3 6.9 368793 530 232 241 0.78 
1 0.3 4.5 12.2 1.9 837565 159 70 70 0.45 
1 0.08 0 12.1 8.2 399936 543 278 278 0.47 
1 0.08 3.2 11.9 3.7 492370 352 183 220 0.25 
1 0.51 0.1 8.7 1.7 434566 438 220 274 0.08 
1 0.2 0 17.4 9.7 352482 1030 565 346 0.08 
1 0.55 0 18.4 14.4 352043 570 248 272 0.08 
2 0.15 16.6 17 4.5 13287 125 61 42 0.35 
2 0 1.3 15.8 0.7 8998 408 198 374 0.06 
2 0 0.4 7.5 4.7 9468 295 101 116 0.5 
2 0.28 0 6.6 6.2 15415 253 97 163 0.32 
2 0.002 1.8 8.6 0.1 16920 398 114 182 0.002 
2 0.002 1 9.4 5.1 13518 414 200 104 0.58 
2 0.72 0.7 4.7 3.4 10518 343 102 102 0.7 
2 0.7 0 19.9 9.4 8812 650 206 452 0.002 
2 0.77 0 23.3 9.7 8140 447 299 190 1.2 
3 0 1.3 17.8 4.8 11991 545 300 401 0.26 
3 0 0 18.3 8.8 9570 712 330 247 0.25 
3 0.1 0 16.2 5 10216 927 350 407 1.09 
3 0 7.8 9.7 3.6 12259 562 270 253 0.35 
3 0 4.2 7.3 1.7 10945 1220 420 475 0.59 
3 0.15 0 12.1 8.2 9826 1011 350 331 0.3 
3 0 3.2 11.9 3.7 9666 482 450 446 0.25 
3 0 0 17.4 9.7 9529 543 390 335 0 
3 1.52 0 18.4 14.4 8714 1087 410 489 0 
Table 5.0.1 Data set for training and testing the 9-5-1 neural network  
Plant: Plant 1 - Ringsend, Plant 2 - Leixlip and Plant 3 - Swords, CarbIn: carbamazepine 
influent concentration (µg/L), Rain: daily rainfall (mm), Temperature: maximum daily 
temperature (0C), Daylight: hours of sunlight per day (h), Flow: flowrate into the plant 
(m3/d), BOD: influent BOD (mg/L), COD: influent COD (mg/L), SS: influent suspended 
solids (mg/L) and CarbOut: carbamazepine effluent concentration. 
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The results of the 9-5-1 configured network are presented in Figure 5.4. 
RMS values for the network were: Training RMS = 6.268 x 10-3, 
Verification RMS = 1.339 and Testing RMS = 0.3521. The training data 
show good correlation while the prediction of testing data is less accurate. 
This may be due to the limited data available for training and testing of the 
network. A larger database would be required to produce a more accurate 
model. The relative effect of the nine inputs were determined using the 
Garson equation (3) where v is the relative effect of the input on the 
output, nv the number of input variables, nh the number of neurons in the 
hidden layer, wkj the absolute value of the weight from the kth input to the 
jth neuron and Oj is the absolute value of the weight from the jth neuron 
(Nί Mhurchί & Foley, 2006). The results indicate that most of the 
parameters have a similar effect (~10%) on the effluent concentration (see 
Figure 5.0.5). However, the quantity of suspended solids in the influent 
stream was shown to have a greater effect (~17%) on effluent 
concentration. 
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Figure 5.0.2 Optimisation of network structure with one hidden layer 
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 Figure 5.0.3 Optimisation of network structure with two hidden layers 
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Figure 5.0.4 Results of training (black) and testing (red) data from the 9-5-
1 network  
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Figure 5.0.5 Relative effect of the nine inputs on the predicted effluent 
concentration in the 9-5-1 network configuration 
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A separate network was constructed for the data from Ringsend WWTP 
(ie. the data in bold in Table 5.0.1). Five neurons in the hidden layer was 
identified as the best configuration (Figure 5.0.6). However, the RMS error 
was better for this network when the data from only one plant were used 
(Training RMS = 4.42 x 10-4; Verification RMS = 5.83x 10-8; Testing RMS = 
0.5776). The resulting training and testing graph is shown in Figure 5.7. 
The relative effect of each of the input variables was calculated for this 
network and it was found that the inputs had approximately equal effect on 
effluent concentrations (Figure 5.0.8). The flow into the plant was found to 
have the least effect on the effluent concentration.  
The results of this ANN analysis show the suitability of artificial 
intelligence for the prediction of pharmaceutical effluent concentration. 
Relative effect analysis completed using the Garson equation presented 
two unexpected results. Firstly, suspended solids were identified as having 
a higher relative effect on carbamazepine effluent concentration (Figure 
5.0.5.) and secondly that flow has less of an effect than the other inputs on 
the effluent concentration (Figure 5.0.8). Both these findings and the 
prediction limitations seen with the networks produced in this study are due 
to the small data set available. A significantly larger data set would be 
required to construct a robust and accurate network.  
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Figure 5.0.6 Optimisation of network structure for one plants data 
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Figure 5.0.7 Results of training (black) and testing (red) data from the 8-5-
1 network  
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Figure 5.0.8 Relative effect of the eight inputs on the predicted effluent 
concentration in the 8-5-1 network configuration
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6.0 Conclusion and future work 
 
The level of pharmaceutical contamination entering the environment in 
WWTP effluents is largely unknown in Ireland. The aim of this research 
was to determine the concentration of twenty compounds released to the 
environment at three locations in the greater Dublin region. The three 
WWTPs are located at Leixlip, Swords and Ringsend. A SPE-LC-MS/MS 
method was developed for the identification and quantitation of the 
selected analytes in both influent and effluent streams. Twenty-four hour 
composite influent and effluent samples were collected from the Ringsend, 
Swords and Leixlip wastewater treatment facilities every month over a 
twelve month period. The presence of selected compounds in both influent 
and effluent samples was investigated. Fourteen of the selected 
compounds were found to be present in samples. The aim of the method 
developed for this analysis was to have one method to analyse for all 
compounds. Because the selected analytes are a range of basic, neutral 
and acidic the development of one method was challenging. While the 
resulting method was successful in analysing for the twenty analytes there 
was a loss in sensitivity. Due to the low levels of analyte present in 
samples a more selective sample preconcentration and detection method 
for each analyte would reduce the limits of detection and quantitation and 
improve the analysis. A method of standard additions was used to 
extrapolate the concentration of each analyte in influent and effluent 
samples. Due to this the confidence limits of the concentrations were 
statistically determined. The confidence limits were very large and showed 
wide variability. This was because two factors. Firstly, a wide variety of 
analytes were analysed in a very complex inconsistent matrix. For this 
reason to accurately quantify each analyte and allow for suppression or 
enhancement of signal intensities a method of standard additions was 
used as opposed to repeat analysis of a sample with no addition. 
Secondly, a limited volume of sample was available monthly and there for 
a maximum of four points could be obtained on any one standard additions 
graph. Increasing the number of data points improves the precision of the 
extrapolated concentration and reduces the confidence limits. Despite the 
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relatively poor confidence limits obtained in this study regression analysis 
on the standard additions gave R2 values of >0.98 in most cases. It is 
therefore thought that the confidence limits in this study are not reflective 
of the accuracy of the data and that extrapolated values are accurate. The 
number of data points analysed for a standard addition graph would need 
to be increased in future work for meaningful confidence limits to be 
determined. 
The concentration of analytes in effluent streams was then compared to 
ecotoxicity data available in the literature. The data currently available 
report LC50 and EC50, however a smaller concentration may still impart a 
negative effect on non-target organisms. In general it was found that the 
determined effluent concentrations were significantly lower than levels 
reported to cause toxicity. However, a cocktail of the selected compounds 
is being released to the environment in the effluent and the combined toxic 
effect of these compounds may be significant. Toxicity data on the effect of 
multiple compounds are limited but some studies have identified a additive 
toxic effect (Cleuvers, 2003). Given the toxicity data available it is thought 
that there is currently no risk to the receiving waters at Ringsend, Leixlip 
and Swords WWTP. 
The concentration of compounds in effluent samples was frequently 
greater than that determined in corresponding influent samples. A 
commonly suggested reason for an increase in concentration during 
wastewater treatment is the deconjugation of metabolites to release the 
parent compound that is then detectable in effluent samples. Matrix effects 
have also been identified as a potential reason for this apparent increase 
in concentration during treatment. The effects of matrix components on the 
analysis of compounds were investigated. The suppression of analyte 
signal was determined using two methods 1) Addition post extraction and 
2) Post column infusion. Both investigations highlighted that the level of 
suppression due to influent matrix components was more significant than 
that observed for the effluent matrix. To further establish the effects of 
matrix components and allow for accurate quantitation of all analytes a 
method of standard additions was used in all monthly samples. Complete 
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suppression of analyte signal in influent samples prevented the analysis of 
some compounds including flurbiprofen, mefenamic acid, diclofenac, 
clofibric acid, sulfamethoxazole and ibuprofen. When an analyte was 
detected in both influent and effluent samples, the analyte response in 
influent samples for the same standard addition was less than that 
observed in effluent samples. These results highlight the negative effect of 
signal suppression on the analysis of influent samples and also call into 
question the hypothesis that an increase in concentration during treatment 
is as a result of deconjugation. Clarification of the major components in 
wastewater samples in future work may improve the analysis and detection 
limits of the analytical techniques by selectively removing the suppressing 
components.  
In this work metal and surfactants were investigated as potential sources 
of suppression. Of the twelve metals analysed only five were detected 
above detection limits and the concentration of those did not reduce 
significantly during treatment. Consequently metal interferences were not 
considered as a potential suppressive agent in influent samples. WWTPs 
have been shown to effectively remove surfactants from wastewater 
streams. The suppressive effect of the surfactant LAS on the analyte 
signal of four compounds was therefore investigated. It was determined 
that LAS completely suppressed the analyte signal for nimesulide. The 
peak shape for trimethoprim changed in the presence of LAS such that it 
was unquantifiable. The peak was split into numerous peaks with no 
baseline separation and the elution occurred over ~ 4 minutes. The signal 
intensity of both mefenamic acid and carbamazepine was less affected by 
the presence of LAS. The signal intensity was not significantly affected and 
while the retention time of the compounds was altered slightly the elution 
time was not lengthened. Thus detection and quantitation with the aid of 
standard additions would be possible. 
Artificial neural networks were used in an attempt to predict the 
concentration of pharmaceutical compounds in effluent streams given a 
set of input parameters. The results indicated that ANNs would be suitable 
for the prediction of effluent concentrations as the prediction of training 
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data was very accurate with R2 values of 1 for plots of predicted against 
actual effluent concentrations. However, prediction of effluent 
concentration in the testing data set was poor. This indicates that a larger 
data set would be required for a full evaluation of the suitability of ANNs. 
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8.0 Appendices 
Appendix A 
 
Sali 
 
Gemf 
 
Diclo 
 
Ibup 
 
Parac 
 
Mefe 
 
Furo 
 
Nime 
 
Sulf 
 
Indo 
 
Beza 
 
Keto 
 
Carb 
 
July 06              
Influent 7.19 <0.03 0.37 5.33 nd 0.66 nd nd nd nd nd nd nd 
Effluent nd 0.23 0.33 4.53 nd 0.49 nd nd 0.33 nd nd nd nd 
Nov 06              
Influent 0.16 nd nd nd nd nd 3.2 nd nd nd nd nd nd 
Effluent nd nd 0.28 nd 0.29 nd 0.6 nd 0.29 nd nd nd nd 
Jan 07              
Influent 1.22 nd 0.16 nd 0.04 nd nd 6.11 nd nd nd nd nd 
Effluent nd nd nd nd 1.07 nd nd nd nd nd nd nd nd 
Feb 07              
Influent 0.07 nd 0.13 0.1 0.05 0.02 nd nd nd nd nd nd 0.29 
Effluent nd 0.15 0.48 1.0 nd 0.27 nd 0.04 0.15 nd nd nd 1.14 
Table A1 Concentrations determined in wastewater treatment samples fro Leixlip using LC-MS technique. 
Concentrations are in µg/L 
nd: analyte was not detected in the sample 
na: analyte was not included in analysis.  
Sali - Salicylic Acid; Gemf – Gemfibrozil; Clof - Clofibric Acid; Diclo – Diclofenac; Ibup – Ibuprofen; Para – Paracetamol; Mefe.- Mefenamic Acid; Furo – 
Furosemide; Nime – Nimesulide; Sulf – Sulfamethoxazole; Indo – Indomethcin; Beza – Bezafibrate; Prav – Pravastatin; Keto – Ketoprofen; Carb- 
Carbamazepine 
 
 II 
 
 
 Sali 
 
Gemf 
 
Diclo 
 
Ibup 
 
Parac 
 
Mefe 
 
Furo 
 
Nime 
 
Sulf 
 
Indo 
 
Beza 
 
Prava Keto 
 
Napr 
 
Sept 06               
Effluent nd nd 0.78 nd nd 1.39 0.39 0.5 0.7 nd nd na nd nd 
Oct 06               
Influent 0.14 nd <0.24 <0.32 0.1 <0.06 5.4 0.02 nd 0.12 nd 0.14 nd 0.02 
Jan 07               
Influent 2.0 nd nd nd 1.1 nd Nd 1.9 nd nd nd nd na nd 
Effluent nd nd 0.51 nd nd 0.54 Nd 1.5 nd nd nd na nd nd 
Table A2 Concentrations determined in wastewater treatment samples from Ringsend using LC-MS technique. 
Concentrations are in µg/L. 
nd: analyte was not detected in the sample 
na: analyte was not included in analysis.  
Sali - Salicylic Acid; Gemf – Gemfibrozil; Clof - Clofibric Acid; Diclo – Diclofenac; Ibup – Ibuprofen; Para – Paracetamol; Mefe - Mefenamic Acid; Furo 
– Furosemide; Nime – Nimesulide; Sulf – Sulfamethoxazole; Indo – Indomethcin; Beza – Bezafibrate; Prav – Pravastatin; Keto – Ketoprofen; Napr- 
Naproxen. 
 
 
 
 
 
 
 
 
 
 
 III 
 
 Sali 
 
Gemf 
 
Clof 
 
Diclo 
 
Ibup 
 
Para 
 
Mefe 
 
Furo 
 
Nime 
 
Sulf 
 
Indo 
 
Beza 
 
Prava Keto 
 
Carb 
 
Dec 06                
Influent nd nd nd 0.32 nd nd nd nd nd nd nd nd na nd Nd 
Effluent nd nd nd 0.37 nd nd 6.27 nd nd nd nd nd na nd Nd 
Jan 07                
Influent 1.97 nd nd 0.08 nd nd 0.97 nd nd nd nd nd nd nd 0.11 
Effluent nd nd nd 0.21 nd 0.03 2.46 nd 6.96 nd nd nd nd nd Nd 
Table A3 Concentrations determined in wastewater treatment samples from Swords using LC-MS technique. 
Concentrations are in µg/L 
nd; analyte was not detected in the sample 
na; analyte was not included in analysis.  
Sali.: Salicylic Acid; Gemf – Gemfibrozil; Clof - Clofibric Acid; Diclo – Diclofenac; Ibup – Ibuprofen; Para – Paracetamol; Mefe - Mefenamic Acid; 
Furo.: Furosemide; Nime – Nimesulide; Sulf – Sulfamethoxazole; Indo – Indomethcin; Beza – Bezafibrate; Prav – Pravastatin; Keto – Ketoprofen; 
Carb- Carbamazepine. 
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Appendix B 
 
Swords Data – Investigation of seasonal variability. 
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Leixlip Data - Investigation of seasonal variability. 
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Appendix D 
 
Ringsend Data - Investigation of seasonal variability. 
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